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Autophagy is one of the main intracellular degradation systems, through which long-lived protein 
and other cytoplasmic compounds are included in double-membrane vesicles, named 
autophagosomes, that fuse with lysosomes to be degraded.   
Several literature data demonstrate the involvement of autophagy in tumorigenesis, highlighting its 
dual role depending on tumor stage and on specific microenvironmental conditions. 
Despite advances in tumor treatments, glioblastoma (GBM) is a still incurable cancer and the relation 
with autophagy is controversial.  
In this regard, this doctoral thesis was aimed at analyse the role of autophagy in GBM 
physiopathology.  
We started from the evidence that autophagy induces mesenchymal to epithelial transition-like in 
GBM cells through down-regulation of SNAI factors, resulting in cadherin up-regulation. Based on 
these observations, we found an impairment of Wnt/β-catenin signalling upon autophagy induction 
in GBM cells. Unlike other types of systems, we also observed a significant re-localization of β-
catenin in sub-membranes areas, associating with N-cadherin. We subsequently investigated the 
expression of EGFR and EGFR-mediated signalling pathways in GBM cells upon autophagy and 
mTOR pathway inhibition. EGFR is frequently overexpressed in GBM, enhancing an aberrant cell 
proliferation. We observed that mTOR inhibition results in the EGFR internalization within the cell, 
delivering the receptor to lysosomes for degradation. As a consequence, an impairment of 
MAPK/ERK pathway, one of the main signalling pathways involved in cell proliferation, occurred. 
Finally, we found Src as a key player in EGFR trafficking. In fact, an increase of Src activation, that 
is commonly required for EGFR phosphorylation, occurs upon mTOR inhibition and is responsible 
for EGFR internalization.  
Taking together, the results collected in this thesis showed that forcing GBM cells to undergo 
autophagy leads to an impairment of intracellular signalling pathways typically hyperactivated in 
GBM and induces cells to acquire epithelial-like phenotype.  
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Autophagy is a highly conserved intracellular process that, along with ubiquitin-proteasome system, 
represents the main intracellular degradation system in eukaryotes (Mizushima, 2018). 
The word “autophagy” derives from the Greek “autòs” (self) and “phagèin” (to eat) and represents a 
straightforward mechanism by which a cell degrades cytoplasmic organelles, proteins and other 
macromolecules. This ubiquitary process normally works at basal levels. However, stressful 
conditions such as starvation, hypoxia and infection can stimulate autophagy, playing an important 
role in cell survival (Wesselborg and Stork, 2015). 
 
   1.1 Types of autophagy 
 
“Autophagy” is normally referred to macroautophagy, the most studied of the three types of 
autophagy in eukaryotic cells, including microautophagy and Chaperone-Mediated Autophagy 
(CMA) (Fig.1). 
 
Macroautophagy consists of double membrane vesicles formation, named autophagosomes, that 
engulf cytoplasmic material and then fuse with lysosomes for degradation, forming autolysosomes. 
Subsequently, amino acids and other simple compounds are recycled after lytic enzyme action (Yang 
and Klionsky, 2010). 
This kind of non-selective degradation can be discriminated from selective autophagy, which leads 
to degradation of mitochondria (mitophagy), peroxisomes (pexophagy), endoplasmic reticulum 
(reticulophagy), nucleus (nucleophagy), lipids (lipophagy) and microorganisms (xenophagy) 
(Wirawan et al., 2012). 
     
Microautophagy, instead, is a non-selective process in which cytoplasmic compounds are directly 
incorporated into lysosome by lysosomal membrane invaginations (Li et al.., 2012). 
 
On the contrary, CMA is a highly selective process in which cytosolic chaperones recognise the 




chaperones to the lysosomal membrane. Substrate proteins are then translocated into the lysosomal 



















Figure 1. Three types of autophagy. Macroautophagy involves the formation of autophagosomes that engulf cargo and 
carry it to lysosomes forming autolysosome. Microautophagy leads to engulf of cytosolic materials directly to lysosome 
thanks to membrane invaginations. Chaperone-mediated autophagy involves KFERQ recognition from chaperones (such 
as HSPA8) that lead proteins to lysosomes, involving LAMP2 on lysosomal membrane (Parzych and Klionsky, 2014). 
 
 
          1.2 Autophagosome formation 
 
Autophagosome formation requires several steps: induction, nucleation, elongation, maturation and 
fusion, and finally degradation and recycle (Gallagher et al. 2016; Wirawan et al., 2012). 
Each step is highly regulated by ATG proteins, coded by Atg (AuTophagy-related Genes) genes, 
whose homologues in yeast have been identified for the first time in 1993 from Tsukada e Oshumi in 
S. cerevisiae (Tsukada and Ohsumi, 1993). 
Nowadays 35 Atg proteins in yeast are known, 15 of these are required for autophagosome formation. 
Functionally, these proteins are divided in six protein complexes: ULK1–ATG13–FIP200–ATG101 
kinases protein complex, PtdIns3K class III with protein core VPS34, VPS15, Beclin 1, ATG9A 
transmembrane protein complex, WIPI/ATG18–ATG2 complex, ATG5/ATG12 coniugation protein 
complex and ATG8/LC3 coniugation protein complex (Fig.2) (Wesselborg and Stork, 2015). 
 


























Figure 2. ATG protein complexes involved into autophagosome formation.  ULK1–ATG13–FIP200–ATG101 
kinases protein complex, PtdIns3K class III whit protein core VPS34, VPS15, Beclin 1, ATG9A transmembrane protein 
complex, WIPI/ATG18–ATG2 complex, ATG5/ATG12 coniugation protein complex and ATG8/LC3 coniugation 




1.2.1 Induction and nucleation 
 
Autophagy is generally maintained at basal levels in physiological conditions, but its activation can 
be strongly enhanced by a plethora of stimuli such as starvation, growth factors shortage, increase of 
intracellular calcium concentration, hypoxia, ATP decrease, and misfolded proteins (Fig.3).  
These signals promote the activation of AMP-activated protein kinase (AMPK), which is responsible 
for the blockade of mTOR (mammalian Target Of Rapamycin) pathway. Notably, the inhibitory 
phosphorylation operated by AMPK on mTOR leads to its dissociation from ULK (Unc51 Like 




Active ULK phosphorylates Ambra1 (Activating molecule in Beclin1 regulated autophagy 1) that 
binds PIK3C3 (Phosphatidil Inositol 3 Kinase Class III) and microtubule associated dynein complex, 
causing the release of the complex from microtubules and its repositioning to the endoplasmic 
reticulum (Fig. 3) (Wirawan et al., 2012; Di Bartolomeo et al., 2010). 
The Isolation Membrane (IM), also known as phagophore, is first membrane needed for 
autophagosome formation and it is thought to be derived from the endoplasmic reticulum (ER). This 
structure starts as a single peri-vacuolar membrane in yeast, and is called PAS (Pre-Autophagosomal 
Structure) (Dunn, 1990; Reggiori and Klionsky, 2013). 
Chiefly, DFCP1 (Double FYVE Domain Conteining Protein 1) localizes to ER areas enriched in 
phosphatidyl-inositol-3-phosphate (PI3P); this event originates membrane structures with a Ω form, 
called omegasomes. For this reason, DFCP1 is considered a key regulation of IM initiation (Axe et 
al., 2008). 
 
Despite the involvement of ER membrane in IM formation, a number of scientific reports 
demonstrates that IM could also originate from other structures, such us mitochondria, TGN, plasma 
membrane and nucleus (Axe et al., 2008; Hailey et al., 2010; Ravikumar et al., 2010; English et al., 
2009). 
During autophagosome nucleation step, PIK3C3 generates PI3P from phosphatidyl-inositol (PI), 
leading to other ATG proteins recruitment: ATG12 binds E1/ATG7 complex and moves to 
E2/ATG10 before binding ATG5 to form ATG12-ATG5 complex (Fig. 3) (Mizushima et al., 2003; 
Kuma et al., 2002).  
 
1.2.2 Elongation, fusion and degradation 
 
ATG12-ATG5 is a crucial complex for the autophagosome maturation and closing as it can interact 
with ATG16L, forming a multimeric complex (Mizushima et al., 2003; Kuma et al., 2002). 
This complex is involved in LC3 (microtubule-associated light chain-3) lipidation. LC3 (also called 
LC3-I) is the homolog of Atg8 and it is both cleaved and conjugated to phosphatidylethanolamine 
(PE) to produce LC3-PE (also called LC3-II), by the combined action of ATG7, ATG3 and the 
ATG16L1 complex (Fujita et al., 2008). LC3-II is normally used as autophagy-specific marker as it 
is, in contrast to LC3-I, specifically localized to the autophagosomal membranes (Kabeya et al., 2004) 
(Fig.3). 
Once autophagosome is completely formed, it moves to lysosome to fuse its membrane with 




hydrolases. Fusion take place by several proteins action, such as LAMP2, Rab (Ras-related GTP 
binding protein), SNARE and LC3 (Tong et al., 2010). 
After the lytic action of hydrolases, resulting amino acids, fatty acids and nucleosides are recycled 











Figure 3. Autophagosome formation.  Autophagosome formation takes place in several steps, starting to autophagy 
induction due to starvation, growth factors shortage, increase of calcium intracellular concentration, hypoxia, decrease of 
ATP, misfolded proteins. mTOR inhibition leads to ULK complex activation that let the autophagosome formation from 
the endoplasmic reticulum (ER). For nucleation, PIK3C3 generates PI3P recruiting ATG12-ATG5 complex involved in 
LC3-II formation. After closure, autophagosome moves to lysosome to be degraded by lysosome hydrolases and the 




1.3 Autophagy regulation  
 
Autophagy is strongly regulated by two upstream protein complexes: AMPK and mTOR complex, 
the major energy-sensing kinases in the cell (Kroemer et al., 2010). 
AMPK is a protein kinase activated by high AMP/ATP levels: with low energy levels, AMPK directly 
or indirectly inhibits mTOR, by phosphorylation (Parzych and Klionsky, 2014).  
mTOR includes two different multimeric protein complex: mTORC1 and mTORC2 (Laplante and 
Sabatini, 2012). They have different functions and rapamycin sensitivity: mTORC1 is inhibited by 
rapamycin and growth factors, controls protein synthesis and it is the major nutrient sensing protein. 
The main mTORC1 targets are the ribosomal protein P70S6 kinase (P70S6K) and Eukaryotic 
translation initiation factor 4E- binding protein 1 (4EBP1) (Jacinto and Lorberg, 2008; Ma and Blenis, 
2009). 
When mTORC1 is active, phosphorylates 4EBP1, inactiving it; conversely, P70S6K phosphorylation 
activates the kinase and stimulates protein synthesis (Ma and Blenis, 2009). 
mTORC2, instead, is insensitive to rapamycin treatment, even though some studies show that chronic 
exposition to rapamycin can inhibit de novo mTORC2 complex formation (Li et al.., 2014). In 
addition, mTORC2 is involved in cellular metabolism and cytoskeleton formation by F-actin 
synthesis (Laplante and Sabatini, 2013). 
 
AMPK and mTORC1 lead to ULK1 phosphorylation, with opposite effects: AMPK operates the 
activating phosphorylation on ULK1, whereas mTORC1 phosphorylation negatively affects its 
activity by preventing ULK1-AMPK interaction (Kim et al., 2011). 
In shortage of amino acids and growth factors in extracellular environment, inhibition of mTORC1 
complex by AMPK leads to its dissociation from ULK1 complex, promoting ULK1 activation and 













Figure 4. Autophagy regulation. Under nutrient rich conditions, active mTORC1 phosphorylates ULK1inhibiting it and, 
as a consequence, inhibiting the autophagy. In contrast, under starvation conditions, active AMPK inhibits mTORC1 and 
phosphorylates ULK1, activating it and leading to Atg13 hyperphosphorylation and autophagy induction (Adapted from 
Yamahara et al., 2013). 
 
 
1.4 Autophagy role in pathology 
 
As described above, autophagy leads misfolded proteins and damaged organelles to degradation in 
order to maintain the normal cellular homeostasis. As a consequence of a dysfunctional autophagy, 
accumulation of abnormal protein aggregates and organelles could cause several diseases. 
Furthermore, several studies have shown that mutations in most ATG genes have pathogenic roles in 
human diseases, most of which are neurodegenerative in nature (Komatsu et al., 2006; Hara et al., 
2006). Accordingly, autophagy defects can be lethal or can leads to severe phenotypes in the 
vertebrates, depending on whether the mutated gene is involved in early or later stages of 
development. For instance, Atg5 -/- and Atg7 -/- mice show protein aggregates and inclusion bodies 
in hepatocytes (Atg7 -/-), cardiomyocytes (Atg5 -/-) and neural cells (Atg5 -/-  or Atg7 -/-) (Wirawan 
et al., 2012; Komatsu et al., 2005; Hara et al., 2006). Atg5 autophagy deficient mice can survive to 
embryogenesis but are going to die during perinatal period because of an incapacity to feed (Di 
Bartolomeo et al., 2010; Kuma et al., 2004) (Fig.5). As shown in figure 5, Ambra1 is one of the main 
autophagy genes whose homozygous mutation leads to embryonic lethality and several defects in the 
central nervous system such us hyperproliferation of the neuroepithelium, midbrain and hindbrain 
exencephaly and defective closure of the neural tube (Di Bartolomeo et al., 2010).  
The role of autophagy in pathophysiology of some disorders is controversial: in the case of 
Huntington’s and Parkinson’s diseases, elevated autophagy level seems related to the pathology 
onset. Conversely, Alzheimer’s disease is linked to altered autophagy due to an autophagy flux 





















Figure 5. Autophagy in mammals development. The involvement of some of the main autophagy genes is shown. 
Depending on the developmental stage, autophagy deficient mice can die before birth or during perinatal period or show 
defects about different organogenesis (Di Bartolomeo et al., 2010). 
 
 
1.5 Autophagy and cancer 
 
The relation between autophagy and cancer is still controversial. Several works show that autophagy 
plays a dual role in cancer depending on tumor stage. In the early stages of tumorigenesis, autophagy 
seems to have an oncosuppressive role. On the other hand, autophagy is likely involved in tumor 
protection during tumor establishment. This is because, during tumor onset, autophagy avoids 
genotoxic molecules accumulation, such as aggregates of ubiquitinated proteins and reactive oxygen 
species (ROS) produced by dysfunctional mitochondria (Mathew et al., 2009). Moreover, autophagy 
is also required to maintain the physiological metabolic homeostasis preventing accumulation of 
damaged organelles and to contrast malignant transformation and genome instability (Green et al., 
2014). 
Furthermore, Beclin1, Atg4, Atg5 and other autophagy markers, have been identified as tumor 
suppressors (Mariño et al.., 2007; Yousefi et al.., 2006). Finally, it is known that the oncosuppressors 
P53 and PTEN are autophagy inducers (Yoon et al., 2012), whereas the oncogene Bcl-2 directly 
interacts with Beclin-1, leading to autophagy inhibition. 
With the establishement of the tumor mass, autophagy is used to promote cells survival in a 




order to escape the response to cancer and drugs (Guo et al.., 2013). For instance, some studies have 
shown that growth factor deprivation can lead to autophagy increase, demonstrating that this process 





   2.1 Classification of Glioma 
 
“Glioma” is a term used to indicate glial cell tumors, mainly originating from astrocytes and 
oligodendrocytes (Chen et al., 2017). To date, the classification by World Health Organization 
(WHO) is the international standard for glioma nomenclature and diagnosis, relying on 
histomorphological criteria. WHO classifies astrocytic glioma in: grade I (Pilocytic astrocytoma, 
rarely causes death), grade II (Diffuse astrocytoma), grade III (Anaplastic astrocytoma) and grade IV 
(Glioblastoma, also known as Glioblastoma multiforme). 
Glial cell tumors originated from oligodendrocytes are classified in Oligodendroglioma (grade II) and 
Anaplastic oligodendroglioma (grade III). Finally, tumor mass originated from both types of glial 
cells are oligoastrocytic tumors, classified in Oligoastrocytoma (grade II) and Anaplastic 
oligoastrocytoma (grade III) (Louis et al., 2007) (Tab.1). 
 
 
Table 1. Glioma classification   
 
Phenotype Subtype    Grade 
Astrocytic tumors Pilocytic astrocytoma I 
Diffuse astrocytoma II 
Anaplastic astrocytoma III 
Glioblastoma IV 
Oligodendroglial tumors Oligodendroglioma II 
Anaplastic oligodendroglioma III 
Oligoastrocytic tumors Oligoastrocytoma II 









2.2 Glioblastoma multiforme 
 
Glioblastoma Multiforme (GBM) is the most common brain tumor in the adult. Compared to women, 
white men are more affected and the median age of patients is 64 years. Despite ongoing research, 
patient life span remains lower than 15 months after diagnosis (Ostrom et al., 2018). 
GBM is often located in cerebral hemispheres, commonly in the supratentorial region, and less often 
in brainstem, in the cerebellum and in the spinal cord (Hanif et al.., 2017). 
It is characterized by a high grade of heterogeneity, vascularization and an infiltrating behaviour. 
Indeed, tumor mass shows poorly delineated margins, that makes it not distinguishable from normal 
tissue. Moreover, it is not common to find distant metastases from site of tumor development, both 
within and outside the Central Nervous System (CNS) (Louis et al., 2007). 
 
2.2.1 GBM subtypes 
 
GBM can be divided in two subtypes, primary and secondary GBMs, that usually evolve in patients 
at different ages. Primary subtype arises de novo in older patients, and represents the most common 
GBM with less aggressive features. It shows several genetic characteristics such as Epidermal Growth 
Factor Receptor (EGFR) amplification, p16 deletion and PTEN mutations. At the other hand, 
secondary GBM is less common than the previous one and slowly arises in younger patients from 
lower grade of astrocytoma. It can show the same features of primary GBM but also p53 gene 
mutations. In both of them, these genetic mutations can lead to an uncontrollable cells growth (Ohgaki 
and Kleihues, 2007). 
GBM can be also classified into four subtypes by gene expression profile: Classical, Mesenchymal, 
Proneural and Neural (Verhaak et al., 2010). 
The first subtype, also named Proliferative subtype, shows chromosome 7 amplification paired with 
chromosome 10 loss, the most frequent event in GBMs. It is often defined by EGFR amplification 
and mutation (mainly vIII EGFR mutation) and PTEN loss. Neural precursors and stem cell markers 
are highly expressed. Furthermore, Classical subtype shows astrocytic features in culture and 
responsiveness to the radio and chemo therapies, that leads to a significantly decrease in mortality 
upon treatments (Verhaak et al., 2010; Van Meir et al., 2010).  
The Mesenchymal type has usually Neurofibromin1 (NF1) gene mutations but also PTEN and TP53 
inactivation. As a consequence of Epithelial to Mesenchymal Transitions (EMT), it shows high levels 
of mesenchymal and astrocytes markers such as CD44. This tumor responds to current chemotherapy 




glioma cell lines display markers patterns similar to the Mesenchymal subtype (Verhaak et al., 2010; 
Van Meir et al., 2010). 
The Proneural type is characterized by PDGFRA (Platet-Derived Growth Factor Receptor-α), IDH1 
(Isocitrate Dehydrogenase 1 gene) and TP53 mutations. It typically shows oligodendrocytic but not 
astrocytic features and usually arises in younger patients, with no survival rate alteration after 
treatments (Verhaak et al., 2010; Van Meir et al., 2010). 
Finally, the Neural type is defined by the expression of neuron markers, with low infiltration 
capabilities and oligodendrocytic and astrocytic differentiation (Verhaak et al., 2010; Van Meir et al., 
2010). 
 
2.3 Therapeutic approaches 
 
To date, standard GBM therapy consists of surgery resection that, when possible, is used to reduce 
the tumor mass size even though, generally, it cannot completely eliminate it. Surgery is usually 
followed by radiotherapy, to kill tumor cells remained after resection, and chemotherapy (Stupp et 
al., 2005). Temozolomide (TMZ) is the most common chemotherapeutic drug now used for GBM 
treatment. It is an oral alkylating agent able to cross the blood-brain barrier and to cause DNA 
methylation in the O6 position of guanine, leading to genomic instability and apoptosis (Daniel et al., 
2019). On one hand this treatment can increase patient lifespan but, on the other hand, TMZ could 
lead to resistance phenomenon, caused by MGMT (O6-methylguanine–DNA methyltransferase) 
overexpression (Hegi et al., 2005). 
Novel approaches are necessary to contrast GBM development. Several studies, indeed, have 
demonstrated that EGFR, PDGFR and VEGFR, as receptors, can be an effective target into GBM 
therapy as well as mTOR/PI3K related targets that could avoid resistance phenomena occurrence in 
GBM (Tabernero, 2007). 
 
3. Autophagy and glioma 
 
Several contradictory studies have shown the dual role of autophagy in tumorigenesis even in glioma. 
It is known that some important autophagy players, such as BECLIN1 but also LC3, are less expressed 
in high-grade gliomas compared to low-grades (Pirtoli et al., 2009; Huang et al., 2010). Furthermore, 
Palumbo and colleagues, in 2012 and in 2014, observed that autophagy has a role in enhancing cell 
radiosensitivity after both Ionizing Radiation (IR) and IR/TMZ treatments, especially when EGFR is 




that an autophagy induction via nutrients starvation or mTOR pathway inhibition, induces a strong 
impairment of both migration and invasiveness in immortalized and primary GBM cell lines, leading 
to a reversion of EMT phenotype (Catalano et al., 2015). 
On the other hand, in 2012 Galavotti et al. reported that some autophagy associated genes, such as 
DRAM1 and SQSTM1, are highly expressed in GBM tumors, leading to a modulation of migration 
and invasion capabilities in Glioma Stem Cells (GSMs) (Galavotti et al., 2012). 
Further investigations about the link between autophagy and glioma are also required in order to 
clarify the possible use of autophagy as trigger in GBM therapy. Indeed, TMZ induces autophagy in 
GBM cell lines but this seems to lead to resistance phenomena, suppressing its anti tumoral effect. It 
has been shown that TMZ cytotoxic effect is recovered by using pharmacological inhibitors of 
autophagy late stages in co-treatments (Kanzawa et al., 2004). On the contrary, a combination of 
TMZ and mTOR inhibitors, that are known to lead to autophagy induction, as well as several 
compounds, for instance cannabinoids (THC), results in autophagy-dependent cell death (Josset et 
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The aim of this doctoral thesis was to deepen the knowledge on GBM biology with a particular focus 
on the autophagy role in signalling pathways involved in cell proliferation and invasion in GBM 
models.  
Although alterations of some autophagy regulators in GBM and their correlation to invasion and 
migration of GBM cells have been already observed, little is known about the autophagy impact on 
GBM onset and progression. Furthermore, it has been recently demonstrated that autophagy 
modulation reverses EMT in GBM cells, switching from a mesenchymal to an epithelial-like 
phenotype through a down-regulation of EMT regulators SNAI.  
Moreover, it is well known that brain tumors, including GBM, frequently show altered autophagy-
associated molecules, such as EGF receptor, resulting in autophagy dysregulation. 
Based on this evidence, we speculated that the autophagy machinery could be alterated in GBM and, 
that autophagy modulation could represent and effective tool to contrast GBM progression.  
To verify this hypothesis, specific goals of the project were: 
 To analyze the effect of autophagy induction on Wnt/β-catenin signalling, a pathway often 
alterated in several cancers, including GBM, and also correlated with EMT (research article I 
and review article, published). 
 To investigate the effects of autophagy modulation on EGFR expression and sub-cellular 
localization and, subsequently, on EGFR-mediated signalling pathways in GBM models 
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Macroautophagy (hereafter referred as autophagy) is an evolutionary conserved and finely 
regulated process, mediating lysosomal degradation of cytoplasmic material, long-lived 
and damaged proteins, and entire organelles [1,2]. During autophagy, double-membrane 
vesicles, named autophagosomes, form and engulf cytoplasmic material, which is then 
delivered to lysosomes for degradation [3]. In shortage of nutrients, mainly aminoacids, the 
nutrient sensor  mTOR is inhibited and Ulk1 complex can drive a massive autophagosome 
formation [4]. Nevertheless, in physiological conditions, a basal level of autophagy 
contributes to maintain the proper cell homeostasis, both during embryogenesis and 
adulthood, and indeed its deregulation has been associated to many human diseases, 
including cancer [5–7]. We have recently demonstrated that autophagy modulation 
regulates the migration and the invasion capabilities of glioblastoma multiforme (GBM) 
cells, by down-regulating epithelial-to-mesenchymal transition (EMT) factors SNAIL and 
SLUG, and, subsequently, up-regulating cadherin expression [8].  
-catenin is a multitasking and evolutionary conserved protein that plays a crucial role in a 
plethora of developmental and homeostatic processes [9,10]. It is, in fact, a structural 
component of the cell-cell adhesion structures, and as a component of the canonical Wnt 
pathway, it regulates cellular proliferation, adhesion, and movement [9,11]. Deregulation of 
Wnt signalling is often associated with initiation, proliferation, and invasion of several 
cancers, including GBM [11,12]; -catenin and other components of the Wnt pathway are, 
in fact, commonly overexpressed and the pathway is constitutively active in GBM [13,14]. 
The Wnt/-catenin pathway plays also a role in EMT, by promoting transcription and 
stabilization of the EMT activators SNAIL and ZEB1 [15,16], or by other mechanisms 
[17,18]. 
Few literature evidence exist on the relationship between autophagy and Wnt/-catenin 


































































the expression of the autophagic adaptor p62, and indeed that nutrient deprivation induces 
-catenin degradation via autophagic machinery [22]. In 2014, Gao et al. demonstrated 
that, in colorectal cancer cells, autophagy negatively regulates Wnt signalling by promoting 
the degradation of the pathway mediator Dishevelled [23]. Moreover, it has been recently 
shown that the anti-helminthic drug Niclosamide induces autophagy and down-regulates 
the Wnt and other pro-survival signal transuction pathways in GBM cells [24]. 
Our findings indicate, for the first time, that autophagy induction attenuates the Wnt 
signalling in GBM cellular models and that it leads to -catenin relocalisation within the 
cell. These findings further support the idea that autophagy modulation could represent a 
potential therapeutical strategy to contrast GBM proliferation and invasiveness. 
 
2. Material and methods 
2.1 Cell culture 
Human GL15 cells were kindly provided by Dr. E. Castigli, Perugia University, Italy. 
Primary human GBM130 cells were obtained, as previously described [25], after surgery at 
Policlinico Umberto I (Rome) from GBM patients that gave a written informed consent to 
the research proposals. The study was approved by the Institutional Ethics Committee of 
Sapienza University and by Ministry of Health. Histopathological typing was done 
according to the WHO criteria resulting as grade IV. Human GL15, U87MG cells and 
GBM130 were cultured in DMEM (Lonza, Basel, Switzerland), supplemented with 10% 
heat-inactivated FBS (Euroclone, Milan, Italy) and 1% penicillin/streptomycin solution 
(Euroclone, Milan, Italy). Cells were grown at 37 °C in a 5% CO2 humidified atmosphere. 
For autophagy induction, cells were cultured in Earle’s Balanced Salt Solution (Sigma 
Aldrich, Milan, Italy) or in the presence of 250 nM Torin 1 (Sigma Aldrich, Milan, Italy ) for 



































































shBeclin and sh-Ctr cells were prepared by lentiviral infection as previously described [8]. 
GL15 cells were infected by incubation with lentivirus containing supernatant for 6 and 8 h 
in presence of 4 g/ml poly-brene. 
 
2.2 qPCR  
Total RNA was isolated with the RNeasy mini kit (QIAGEN, Hilde, Germany). 1 µg RNA 
was retrotranscribed using M-MLV enzyme and oligodT (Promega, Madison, Wisconsin, 
USA). qPCR was performed using SYBR GREEN PCR Master Mix Applied Biosystems 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA), with the QuantStudio 12K Flex 
Applied biosystem. The following pairs of primers were used: axin2 (5′-
AGTGTGAGGTCCACGGAAAC-3'; 5ʹ-CTTCACACTGCGATGCATTT-3'), cyclin D1: (5ʹ-
CTGGCCATGAACTACCTGGA-3′; 5′-CTCCGCCTCTGGCATTTTGG-3ʹ); c-myc: (5′-
AGCGACTCTGAGGAGGAACA-3′; 5′-CTCTGACCTTTTGCCAGGAG'); β2m (5′-
CTCCGTGGCCTTAGCTGTG-3′; 5′-TCTCTGCTGGATGACGTGAG-3′ ). mRNA 
expression level for the genes of interest was calculated by means of the ddCt method, 
with β2m expression as standard. The mRNA levels were then expressed as variations in 
respect to the control condition. Reported values are the means of three independent 
biological replicates. 
 
2.3 Western blotting and antibodies 
Proteins were separated by means of SDS-PAGE and electroblotted onto nitrocellulose 
(GE Healthcare, Life Sciences, Little Chalfont, Buckinghamshire, UK). Membranes were 
incubated with primary antibodies diluted in PBS/5% non-fat dry milk/0.1% Tween-20 
overnight at 4°C. Detection was achieved using horseradish peroxidase-conjugated 
secondary antibody (Bio-Rad Laboratories, Milan, Italy) and visualized with ECL plus (GE 


































































antibodies were used: anti-p62 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
LC3B (Cell Signaling, Danvers, MA, USA), anti-BECN1 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), anti-β-catenin (BD Biosciences, Franklin Lakes, New Jersey, USA), anti-
active β-catenin (S37/T41) (Millipore, Billerica, MA, USA), anti-Dvl2 (Cell Signaling, 
Danvers, MA, USA), anti-Lamin A/C (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-LDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti- β-Actin (Sigma 
Aldrich, Milan, Italy).  
 
2.4 Cell lysis and subcellular fractionation 
The appropriate amount of Nucleus Buffer (1 mM K2HPO4, 14 mM MgCl2, 150 mM NaCl, 1 
mM EGTA supplemented with 0.1 mM DTT, 0.3% Triton and protease inhibitor cocktail) 
were added to pelletted cells and, after incubation on ice for 30 min, centrifuged at 850 g 
for 10 min, to isolate the nuclear fraction. Nuclei were washed twice with fractionation 
buffer, centrifuged as above and resuspended in RIPA Buffer (50Mm Tris HCl pH 7.4, 
Triton 1%, Na Deoxycholate 0.25%, SDS 0.1%, 150 mM NaCl, 1 mM EDTA, 5 mM MgCl2 
supplemented with protease inhibitors cocktail). Samples were then briefly sonicated (Hold 
6 constant, 30’’). Proteins concentration was determined using Lowry protein assay (Bio-
Rad, Hercules, CA, USA). 
 
2.5 Immunocytochemistry and confocal analysis 
Cells were grown on coverslips and fixed with 4% PFA in PBS, followed by 
permeabilization with 0.1% Triton X-100 in PBS. β-catenin (BD Biosciences, Franklin 
Lakes, New Jersey, USA) and N-cadherin (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) primary antibodies were incubated overnight at 4°C and visualized by means of 
Alexa Fluor (Invitrogen, Carlsbad, CA, USA). Coverslips were mounted in antifade 


































































(TCS SP8; Leica, Wetzlar, Germany), equipped with a 40x 1.40–0.60 NA HCX Plan Apo 
oil BL objective at RT. 
Regarding ImageJ software analysis, the pixels of two 8-bit images (red and green 
channels of each image) are considered colocalized if their intensities are higher than the 
threshold of their channels (set at 50) and if the ratio of their intensity is higher than the 
ratio setting value (set at 50%). Colocalization was assessed by calculating the Pearson’s 
correlation coefficient r of at least 10 cells analyzed in two independent experiments. The 
Pearson’s correlation coefficient was expressed as mean ± SD. The fluorescence intensity 
of each fluorochrome was simultaneously analyzed and plotted. 
 
2.6 Statistical analysis 
All experiments were performed at least three times. Sigma Plot software was used for 
statistical analysis. Statistical significance was determined by using the Student’s t-test. P 
value ≤ 0.05 was considered significant. 
 
3. Results 
3.1 Wnt/-catenin signalling is negatively regulated by autophagy in GBM cells 
In order to analyse the effect of autophagy induction on Wnt signalling in GBM cells, 
autophagy was induced by means of 18 hours aminoacid- and serum-starvation (EBSS 
treatment) in GL15 and U87MG cells, as previously described [8] and as shown in Fig. 1a. 
qPCR analysis has been performed to measure the relative mRNA levels of the -catenin 
target genes axin2, cyclinD1 and c-myc in both control and in EBSS-starved cells. We 
observed a significative reduction in axin2 and cyclinD1 mRNA levels in both EBSS-
treated GL15 and U87MG cell lines, in respect to control cells, grown in nutrient-rich 
medium (Fig. 1b). Similar results were obtained when autophagy was induced by culturing 


































































S1a and b). Differently from other cellular systems, we could not detect any significative 
variation of c-myc mRNA levels in cells grown in EBSS or in Torin presence (Fig. 1b and 
not shown). In order to prove the role of the autophagic process in promoting -catenin de-
activation upon nutrient starvation, we knocked down the autophagy regulator Beclin1, by 
means of specific siRNA. GL15 cells lacking of Beclin1 showed a reduced basal 
autophagy levels, and a decreased capability to accumulate LC3II and to degrade p62 
substrate upon nutrient deprivation (Fig. 1c). In addition, the reduction of -catenin target 
genes mRNA, that we observed in control cells upon nutrient deprivation, was prevented 
by Beclin1 silencing, almost completely for axin2 and, at lesser extent for cyclinD, that is 
much more responsive to starvation (Fig. 1d). Moreover, a slight, but significative, increase 
of the basal level of cyclinD mRNA was observed in Beclin1-defective cells in nutrient-rich 
conditions thus further suggesting role for autophagy in modulating Wnt/-catenin 
signalling (Fig. 1d). 
 
3.2 Dishevelled protein is degraded upon autophagy induction  
Dishevelled (Dvl) protein is a component of the protein family that mediates Wnt pathway 
by binding to Frizzled receptor and by inhibiting the APC-containing destruction complex 
[26]. Negative modulation of Wnt signalling has been linked to Dvl degradation upon 
autophagy induction in HEK293 and in colorectal cancer cells [23]. 
We analyzed the expression level of Dvl2 and, similarly to what observed in HEK293 cell 
line, both GL15 and U87MG cells showed an appreciable reduction of the protein upon 
autophagy induction (Fig. 2a and Supplementary Figure S1c). The same result was 
obtained   


































































On the other hand, no variation in Dvl2 protein levels was observed in Beclin1-devoid 
cells, thus demonstrating that autophagy induction is necessary for Dvl2 degradation (Fig. 
2b). 

3.3 The expression level of the transcriptional active -catenin decreases upon 
autophagy induction 
In 2013, Petherick et al. have demonstrated that nutrient deprivation leads to proteasome-
independent and autophagosome-mediated -catenin degradation in colorectal carcinoma 
cells, that was likely responsible for Wnt/-catenin signalling inactivation [22]. Moreover, 
Cheng et al. have been shown that Niclosamide induces autophagy and -catenin 
degradation in GBM cells [24] . To test if -catenin was degraded upon nutrient deprivation 
in glioma models, we analysed -catenin amount by western blot, and we did not observe 
any difference in the total protein levels between control and 18 h-starved GL15 and 
U87MG cell lines. However, by means of an antibody specifically directed against the de-
phosphorylated (S37/T41) -catenin, we observed a significative decrease of the nuclear 
transcriptionally active protein pool in autophagic glioma cells in respect to control cells 
(Fig. 3a and Supplementary Figure S1c). This reduction of the active -catenin pool was 
not observed in Beclin1-devoid cells, thus suggesting a direct involvement of Beclin1-
dependent autophagy in -catenin transcriptional activity (Fig. 3b). 
 
3.4 Autophagy induction induces -catenin relocalisation in GBM cells 
In line with the so far obtained results, we observed, by means of subcellular fractionation 
experiments, a significative reduction of the -catenin nuclear fraction and a slight increase 
in the cytosolic one, upon 18 hours of EBSS- and Torin- culturing in the cell lines analyzed 


































































in the -catenin nuclear fraction upon starvation was completely prevented in GL15 cells 
lacking of Beclin1 protein although no difference in the -catenin nuclear basal level was 
observed (Fig. 4b). In order to verify a possible re-localisation of the cytosolic -catenin 
pool, we analyzed the protein's expression pattern in GL15 and in U87MG glioblastoma 
cells by immunocytochemistry. Widespread expression of the protein within the cells was 
observed in control conditions (Fig. 4c, upper panels), whereas a relevant accumulation of 
-catenin in sub-plasma membrane areas was observed in cells cultured for 18 hours in 
EBSS (Fig. 4c, bottom left and middle panels) or in Torin presence (Supplementary Figure 
S1e, middle panels and not shown), but not in Beclin1-silenced GL15 cells (Fig. 4c, bottom 
right panel). Strikingly, we observed a clear enlargement of the cells and the appearance 
of cell-cell contacts, highlighted by -catenin signal, that were almost completely absent in 
control cells (Fig. 4c and Supplementary Figure S1e).  
  
3.5-catenin associates with N-cadherin upon autophagy induction  
Based on the evidence of -catenin relocalisation in sub-plasma membrane areas, that 
suggested a possible interaction with membrane proteins involved in cell-cell interactions, 
we then analyzed N-cadherin localisation within glioma cells in our experimental 
conditions. Confocal analysis showed a diffuse N-cadherin intracellular localization in 
U87MG and GL15 control cells (Fig. 5, left upper panels). Conversely, in EBSS-cultured 
cells, N-cadherin staining overlapped with -catenin signal in correspondence of cell-cell 
contacts (Fig. 5). The same result was observed in Torin-treated U87MG (Supplementary 
Figure S1e, bottom panels). This result suggested that autophagy induction promotes the 
association between -catenin and N-cadherin in glioma cells, and that this event is likely 




































































A number of studies report Wnt signalling as aberrantly activated in GBM, thus promoting 
tumour growth and propagation, by transcriptional activation of multiple target genes, 
involved in both proliferation and invasion [13]. In the recent years, it has been reported 
that in HEK293 and in colorectal cancer cells, Wnt signalling could be attenuated under 
nutrient deprivation by accelerating autophagy-mediated Dvl degradation [23]. In addition, 
in nutrient-stressed colorectal cancer cells, -catenin can be per se a direct target of 
autophagic degradation, in a proteasome-independent manner [22]. -catenin down-
regulation and Wnt pathway inhibition has been also observed in a GBM cellular model 
treated with the anti-helminthic drug Niclosamide, that is also able to induce autophagy, 
although the mechanism of action remains to be elucidated [24]. 
Here we demonstrate that autophagy induction negatively regulates Wnt/-catenin 
signalling in GBM cellular models. We report, for the first time, that nutrient starvation and 
m-TOR inhibition strongly attenuate cyclinD1 and axin2 transcription, through an 
autophagy-dependent mechanism, as suggested by the rescue observed in Beclin1 
silenced cells. Conversely, c-myc transcription (and n-myc too, data not shown) is not 
affected by nutrient starvation or by m-TOR pharmacological inhibition, thus suggesting a 
Wnt-independent regulation of myc genes in GBM cells. The decrease in Dvl and in axin2 
expression that we observed could explain, at least partially, the impairment of Wnt/-
catenin signalling obtained. 
We also found that autophagy activation by nutrient deprivation or by m-TOR inhibition 
does not result in -catenin degradation in GBM cells, as observed in a colorectal model, 
but, surprisingly, we observed that autophagy promotes -catenin relocalisation within the 
cell. In fact, we observed a decrease of the -catenin nuclear fraction, coupled to an 


































































demonstrated a different signal distribution of the protein among nutrient rich- and nutrient 
poor- conditions. Upon autophagy induction, -catenin appears mainly localized in sub-
membrane areas where it decorates the cell-cell contacts which are much more evident 
than in control cells. The appearance of an epithelial-like phenotype of these cells was 
confirmed by the co-localisation of -catenin with N-cadherin, in correspondence of the 
cell-cell contacts.  
By our previous observations, we know that N- and R-cadherin mRNA level increase in 
glioma cells upon autophagy induction, likely as consequence of Snail1/2 down-regulation 
[8]. The role of N-cadherin in EMT is not completely understood. In epithelial tumours 
(carcinomas), in fact, the cadherin switch, from E- to N-isoform, is thought as a hallmark of 
EMT occurrence [27,28], but the contribution of cadherin isoforms in glioma EMT is less 
documented. It has been demonstrated that expression of N-cadherin inversely correlates 
with the invasive behaviour of GBM cells [29,30], and the instability and disorganisation of 
cadherin-mediated junctions are likely associated to GBM invasive behaviour [31,32]. Our 
data are consistent with a newly acquired role for -catenin in supporting the EMT reverse 
process (mesenchymal-to-epithelial-like transition, MET) observed in glioma cells when 
they are forced to undergo autophagy [8]. 
The role of autophagy in GBM pathogenesis is still a matter of debate [33,34]; autophagy 
induction has been observed in GBM in response to radio- and temozolomide-based 
therapy and even though a number of clinical trials aimed at inhibiting autophagy 
execution, mainly by Chloroquine, have been launched, others directed to inhibiting mTOR 
pathway and thus activating autophagy, are ongoing [35,36]. Although further studies are 
necessary to better dissect autophagy role in GBM progression, our findings support the 
idea that autophagy modulation could represent a potential therapeutical strategy to 




































































GBM is the most common and lethal adult brain tumour and it is characterized by a highly 
invasive behaviour. An aberrantly activated Wnt/-catenin signalling is thought responsible 
for GBM invasion capability, beside for tumour proliferation, and stemness maintenance.   
We have found that autophagy negatively regulates Wnt/-catenin signalling in 
glioblastoma cellular models. Moreover, we observed that -catenin relocalises within the 
GBM cell and associates with N-cadherin, thus contributing to mesenchymal-to-epithelial-
like transition. The findings reported here add important clues for the definition of possible 
therapeutical strategies, targeting the autophagic process, to contrast GBM progression. 
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Figure legends 
Figure 1 Autophagy induction reduces Wnt signalling. (a) GL15 and U87MG cells 
were cultured in DMEM (Ctr) and aminoacid- and serum- free medium (EBSS) for 18 h, in 
presence or not of 20 M Chloroquine (CQ). Western Blot analysis of autophagy markers 
P62 and LC3 I/II was used to check autophagy induction. β-ACTIN was used as loading 
control. The blots are representative of three independent experiments. (b) mRNA 
expression levels of axin2, cyclin D1 and c-myc obtained by qPCR on GL15 (left panel) 
and U87MG (right panel) cultured in DMEM (Ctr) and aminoacid- and serum- free medium 
(EBSS) for 18 h. The graphs represent the mean ± SE of three different experiments. 
Statistical significance: * P≤ 0.05; *** P≤ 0.001; **** P≤ 0.0001. (c) GL15 were transduced 
with a scramble RNA (shCtr) or with a BECN 1-directed shRNA (shBECLIN) and were 
grown in DMEM (Ctr) or EBSS for 18 h. Western Blot analysis of autophagy markers P62 
and LC3 I/II was used to check autophagy induction. An antibody specific for BECLIN1 
was used in order to check the silencing efficiency. β-ACTIN was used as loading control. 
The blots are representative of three independent experiments. (d) mRNA expression 
levels of axin2 and cyclin D1 obtained by qPCR on GL15 cells after lentiviral infection with 
scramble RNA (shCtr) or BECN-1-directed RNA (shBECLIN) grown in DMEM (Ctr) or 
EBSS for 18 h. The graph represents the mean ± SE of three different experiments. 
Statistical significance: * P≤ 0.05; ** P≤ 0.01; *** P≤ 0.001. 
 
Figure 2 Autophagy regulates Dishevelled protein levels in GBM cell lines. Western 
blotting of protein extracts from GL15, U87MG and GBM130 (a) and shBECLIN1 GL15 
cells (b), cultured in DMEM (Ctr) or EBSS, was performed by using a specific antibody for 
Dishevelled 2 (DVL2). β-ACTIN was used as loading control. The graphs represent the 
mean ± SE of three different experiments. Statistical significance: * P<0.05 Student t-test.  
 
Figure Legends
Figure 3 β-catenin activity is reduced in GBM cells upon autophagy induction. 
Western blotting of protein extracts from GL15, U87MG, GBM130 (a)  and shBECLIN1 
GL15 cells (b), cultured in DMEM (Ctr) or EBSS was performed by using specific 
antibodies for the total (β-catenin) and the dephosphorylated (S37/T41) form of β-catenin 
(active β-catenin). β-ACTIN was used as loading control. The graphs indicate the relative 
ratio between active/total β-catenin and represent the mean ± SE of three different 
experiments. Statistical significance: * P<0.05; ** P≤ 0.01 Student t-test.  
 
Figure 4 Autophagy induces β-catenin subcellular relocalisation. (a) After subcellular 
fractionation experiments in GL15 and U87MG cultured in DMEM (Ctr) or EBSS for 18 h, 
Western blotting of protein extracts was performed by using a specific antibody for β-
catenin. Lamin A/C and LDH were used as loading controls for nuclear and cytosolic 
fractions, respectively. The graph indicates the ratio between β-catenin and Lamin A/C (for 
nuclear expression) and β-catenin and LDH (for cytosolic expression) in EBSS compared 
to control cells in three independent experiments. N, nuclei; C, cytosol. Statistical 
significance: * P<0.05; ** P≤ 0.01 Student t-test. (b) The same experiment was performed 
in GL15 transduced with a scramble RNA (shCtr) or with a BECN 1-directed shRNA 
(shBECLIN) grown in DMEM (Ctr) or EBSS for 18 h. The graph indicates the ratio between 
β-catenin and Lamin A/C (for nuclear expression) and β-catenin and LDH (for cytosolic 
expression) in EBSS compared to control cells in three independent experiments. N, 
nuclei; C, cytosol. Statistical significance: ** P≤ 0.01 Student t-test. (c) U87MG, GL15 and 
shBECLIN1 GL15 cells grown in DMEM (Ctr) or EBSS medium were subjected to 
immunocytochemistry and confocal analysis for β-catenin localisation (red). Arrowheads 
indicate cell-cell contacts. Scale bar, 30 µM. 
 
Figure 5 β-catenin and N-cadherin colocalise upon autophagy induction. U87MG and 
GL15 cells grown in DMEM (Ctr) or EBSS medium were subjected to 
immunocytochemistry and confocal analysis for N-cadherin (green) and β-catenin (red) 
localisation. Inset containing higher magnification views of the merge images are also 
shown. Scale bar, 30 µM. Colocalisation index was assessed by calculating the Pearson’s 
correlation coefficient r of at least 10 cells analysed in two different experiments (mean r : 
Ctr, 0.20 ± 0.02; EBSS, 0.72 ± 0.07 for U87 and mean r : Ctr, 0.15 ± 0.02; EBSS, 0.66 ± 
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Abstract: Epithelial-to-mesenchymal transition (EMT) and its reverse process MET naturally occur
during development and in tissue repair in vertebrates. EMT is also recognized as the crucial event
by which cancer cells acquire an invasive phenotype through the activation of specific transcription
factors and signalling pathways. Even though glial cells have a mesenchymal phenotype, an EMT-like
process tends to exacerbate it during gliomagenesis and progression to more aggressive stages of
the disease. Autophagy is an evolutionary conserved degradative process that cells use in order to
maintain a proper homeostasis, and defects in autophagy have been associated to several pathologies
including cancer. Besides modulating cell resistance or sensitivity to therapy, autophagy also affects
the migration and invasion capabilities of tumor cells. Despite this evidence, few papers are present
in literature about the involvement of autophagy in EMT-like processes in glioblastoma (GBM) so
far. This review summarizes the current understanding of the interplay between autophagy and
EMT in cancer, with special regard to GBM model. As the invasive behaviour is a hallmark of GBM
aggressiveness, defining a new link between autophagy and EMT can open a novel scenario for
targeting these processes in future therapeutical approaches.
Keywords: autophagy; epithelial-to-mesenchymal transition (EMT); glioblastoma (GBM); cadherins;
Wnt/β-catenin signalling
1. Introduction
Glioblastoma (GBM) is the most malignant and frequent form of glioma. This brain tumor is
derived from glial cells and is characterized by high proliferation rate and local dissemination. Despite
the improvement of chemo- and radio-therapies obtained in last decades, GBM prognosis is very poor
with a median survival time that rarely exceed 18 months. Notably, GBM is characterized by resistance
to apoptosis and high invasiveness, driving the search for novel targets useful to design effective
therapeutical strategies.
The Epithelial-to-Mesenchymal Transition (EMT) programme is considered to be crucial for the
acquisition of an invasive phenotype in epithelial cancer cells. Although some differences have been
outlined, glioma cells also undergo an EMT-like process, through the activation of specific transcription
factors and signalling pathways. Considering the critical role played by EMT on GBM dissemination,
resistance to apoptosis and maintenance of cancer stem cells staminality, a number of preclinical
studies have been launched to target the process as therapeutic approach.
In addition, the role of autophagy in tumor onset, progression is acquiring increasing clinical
inerest. For instance, it has been recently shown that, besides modulating cell resistance or sensitivity
to therapy, autophagy can also modulate GBM invasion.
Cancers 2019, 11, 312; doi:10.3390/cancers11030312 www.mdpi.com/journal/cancers
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In this review, we examined the current understanding of the role of autophagy in regulating
the EMT and EMT-like programmes and in directing GBM cells to a more or less invasive phenotype.
Moreover, we provided some clues to argue that blocking autophagy for therapeutic purposes requires
careful consideration.
2. Epithelial-to-Mesenchymal Transition
EMT is a biological process by which epithelial polarized cells undergo various biochemical
modifications that convert them in mesenchymal, isolated, and not-polarized cells. A lot of evidence
suggests that EMT and its reverse process (mesenchymal-to-epithelial transition, MET) are crucial for
tissue remodeling during development, wound repair and the initiation of cancer metastasis. In the
early 1980s, Elizabeth Hay described epithelial-to-mesenchymal phenotype changes in the primitive
streak of chick embryos [1]. Initially named as “epithelial to mesenchymal transformation”, this
process is now known as “epithelial-to-mesenchymal transition” to emphasize its transient nature and
to distinguish it from the neoplastic transformation. To acquire a mesenchymal phenotype, epithelial
cells undergo morphological and biochemical changes, reorganize their cytoskeleton, and activate
a specific transcriptional programme. Indeed, epithelial cells are characterized by an apical-basal
polarity, a polygonal shape and various kind of junctions. The latter tightly holds epithelial cells
against each other and anchors them to the basement membrane, thus ensuring the structural integrity
of epithelial sheets within the body tissues [2]. Conversely, mesenchymal cells exhibit a spindle-like
morphology, do not have any polarity or connection with other and they are loosely anchored to the
extracellular matrix (ECM) by focal adhesions.
Transcription factors (TFs) belonging to the SNAI family, named Snail and Slug, the zinc-finger
E-box-binding homeobox (ZEB)1/2, and Twist1/2 are recognized to be the master regulators of EMT
execution, since they promote the transcription of genes normally expressed in mesenchymal cells, such
as N-cadherin, vimentin, and fibronectin. On the contrary, they suppress the expression of the epithelial
markers E-cadherin, claudins, occludins, and cytokeratins. Loss of E-cadherin, in turn, promotes
Wnt signaling and β-catenin accumulation in the nucleus, where it activates Tcf/LEF-dependent
transcription of genes promoting proliferation and migration [3].
Cells undergoing EMT lose their apical–basolateral polarization and acquire a fibroblast-like
morphology that allow them to degrade the underlying basement membrane and to migrate from the
epithelial layer in which they originated [4]. Metalloproteases are also activated during EMT, and favor
cell migration by degrading the membrane basement and the extracellular matrix components [2].
Furthermore, it has been shown that noncoding microRNAs play a role in EMT, by regulating the
translation of EMT players, as extensively addressed in Abba et al. [5].
EMT can be classified in three different subtypes according to EMT meetings discussion: the
so-called “type 1” EMT occurs during implantation, embryogenesis and organogenesis, the “type 2”
EMT is associated to wound healing, tissue regeneration and organ fibrosis, and the “type 3” EMT
characterizes neoplastic cells during metastatization. For a comprehensive overview of type 1 and
type 2, refer to Kalluri et al., 2009 [4]. The activation of a “type 3” EMT programme (hereafter referred
to as EMT) has been proposed to be pivotal for the acquisition of a malignant phenotype by cancer
cells [6], as discussed below in detail.
2.1. Signals Stimulating Epithelial-to-Mesenchymal Transition in Cancer
Epithelial carcinoma cells, and typically those present at the external part of the tumoral mass,
can acquire a mesenchymal phenotype upon specific stimuli. The microenvironment surrounding the
primary tumor (TME) is characterized by inflammation, hypoxia, ECM components and tissue-specific
soluble factors [7]. Notably, tumor cells recruit activated fibroblasts and immune cells that secrete
cytokines, that, in turn, can activate the EMT programme. TGF-β is secreted by stromal fibroblasts,
platelets and tumor cells themselves, and is considered the main EMT activator as it induces the
expression of specific TFs in different cancer models [8–10].
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Among cytokines, Tumor Necrosis Factor-α (TNFα) is crucial for EMT induction, and its effects
are mediated through NFκB signaling pathway activation [11–13]. It has been also described
that interleukins, particularly IL6, released by TME cells, can contribute to EMT stimulation.
Other EMT-inducing signals originated from the tumor stroma are represented by growth factors such
as HGF, EGF, PDGF that are able to activate EMT-specific TFs [14–17].
Furthermore, tumor microenvironment is characterized by hypoxia that promotes EMT via
hypoxia-inducible-factor-1α (HIF1α) activation [18,19]. HIF1α stimulates inflammatory cytokines [20]
and cooperates with Wnt/β-catenin signaling to enforce the EMT induction [21]. Moreover, during
hypoxia, mitochondria increase the production of reactive oxygen species (ROS) that further contribute
to EMT activation via both stimulating NFκB signaling [22], ECM regulation and cytoskeleton
remodeling [23].
Once they have acquired a mesenchymal phenotype, cancer cells can dissociate from the primary
mass, migrate and eventually enter the blood vessels by intravasation to initiate the metastatic process.
Following extravasation and micrometastases formation, invading cells activate a MET programme
and form macroscopic metastases resembling the epithelial features of the originating primary tumor,
although the molecular mechanisms of MET have been less investigated if compared to those regulating
EMT. However, both EMT and MET activation seem to be highly tissue-specific and strictly dependent
on the local microenvironment encountered [2,6,24,25].
2.2. Epithelial-to-Mesenchymal Transition in Glioblastoma Dissemination
EMT has been mainly characterized in carcinoma models, and the role of EMT in glioma has
only recently been investigated [26–28]. Candidate cells for originating gliomas (cells of origin)
are mostly neural stem cells (NSCs), normally present in the adult brain, and oligodendrocyte
precursor cells (OPCs) [29–32]. However, the involvement of more differentiated cells cannot be
completely excluded [33]. As a consequence of the neurodevelopmental process, neural cells assume a
mesenchymal phenotype, different from the epithelial one typical of the ectodermal cells they derive
from. Therefore, gliomas do not undergo the classical EMT programme during tumorigenesis, and
the terms “EMT-like” or “glial-to-mesenchymal transition (GMT)” have been proposed to indicate
this peculiar process [34]. Although it is not clear whether cells of origin undergo or not significant
modifications toward more mesenchymal features, glioma cells show a high plasticity in terms of
EMT-like/MET-like conversion, likely mediated by epigenetic alterations induced by the tumor
microenvironment [35,36]. Based on The Cancer Genome Atlas (TCGA) classification, GBMs can
be differentiated into four genetic subtypes: Mesenchymal, Classical, Neural and Proneural [37].
Verhaak results suggest that Proneural GBM patients do not have a survival advantage from aggressive
therapeutical treatments, unlike Classical and Mesenchymal GBM patients [37]. Role of EMT in each
GBM genetic subtype has been investigated by Zarkoob et al. in 2013 [38]. A significant overlap
between the genes that are up-regulated in the EMT signature and those that are up-regulated in
each of the GBM subtypes exists, although, among all, the mesenchymal subtype has the highest
number and expression levels of up-regulated genes [38]. Indeed, GBMs belonging to the mesenchymal
subtype are characterized by an elevated invasive potential, poor clinical prognosis, and significantly
shortened time to recurrence following initial treatment, compared to the other subtypes. The most
commonly used glioma cell lines also present a predominant mesenchymal signature.
GBM cells in the invasive front, differently from those of the inner mass, commonly execute an
invasion programme characterized by detachment from the mass, direct adhesion and degradation
of ECM (lack of basement membrane) and widespread dissemination in the surrounding brain
tissue. Remarkably, unlike other tumors, GBMs only rarely form metastases outside CNS,
even though a hallmark of their aggressiveness is the infiltration and the diffuse growth in the
surrounding parenchyma.
Large-scale genetic analyses have suggested that signaling networks activated during the
physiological neural development are also employed by GBM cells to promote tumor growth and
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invasion [39–41]. In detail, pathways mediated by Wnt/β-catenin, TGF-/β, Tyrosine kinase receptors
and SDF/CXCR4 have been involved in the activation of EMT-like related genes to promote GBM
dissemination [26,27]. Kahlert et al. found that the Wnt/β-catenin pathway is predominantly
activated within cells located at the invasive peritumoral front of patient specimens belonging to
the mesenchymal subtype. Chiefly, it induces the expression of Zeb1, Twist1 and Slug, thus promoting
the migratory capability of GBM cells in vitro [42].
Regarding TGF-β pathway, a number of evidence demonstrated its critical role for the promotion
of invasive properties of glioma cells [43–45], although the molecular mechanisms involved need to
be further investigated. Interestingly, TGF-β signaling is known to be crucial in the maintenance of
the mesenchymal stem-like population in GBM [45,46]. ZEB1 seems to be the pivotal mesenchymal
transcription factor activated by TGF-β signaling since, differently from Snail, Slug and Twist, it
accumulates in the nucleus of GBM cells [47].
The Hepatocyte growth factor (HGF) binding to the tyrosine kinase receptor c-MET is another
crucial event highly activated. c-MET is overexpressed within GSC populations [48] and in
patient-derived GSCs belonging to the mesenchymal subtype [49]. Accordingly, elevated c-MET
signaling enhances GSC migration by activating EMT TFs [49,50] and is associated with poor survival
and increased tumor invasiveness in patients [51–53].
The majority of molecules involved in the classical EMT have also been shown to play also a role
in the EMT-like process. An increased activity of the TFs that mainly orchestrate the typical EMT, such
as SNAI proteins, ZEB1/2, and Twist, promotes the invasion of GBM cells [54–57]. For instance, SNAIL
silencing reduces invasion, migration and proliferation in GBM cell lines [58,59] and overexpression
of Slug correlates with GBM grade [56]. ZEB1 and ZEB2 expression is also correlated with invasive
features and with survival of GBM patients; ZEB1 knock-down cells formed less invasive and more
drug-sensitive masses than wild type cells when inoculated in mouse brain [54,60]. Moreover,
Twist1 and Twist 2 expression, besides affecting stemness properties, has been associated to the
invasive properties of GBM cells as it mediates the expression of crucial EMT-related genes such as
metalloproteinase 2 (MMP2), Slug and HGF among others [57].
It is worth mentioning that the classical cadherin switch, which is widely accepted as an EMT
hallmark in carcinomas, is a controversial matter in GBM. Differently from carcinomas, E-cadherin
expression is almost absent in neural tissues, where its expression appears limited to GCSs cells and to
a subset of highly aggressive GBM cells. Otherwise, N-cadherin is absent in epithelial tumors before
the EMT execution, whereas is highly expressed in astrocytes, where it contributes to regulate cell
polarity and migration and in GBM cells, that show a faster and less-directed movement to respect to
astrocytes [54,61]. It was found that N-cadherin expression is inversely correlated with the invasive
behaviour of GBM, and its ectopical expression reduces cell migration and restores polarity in GBM
cells [62,63]. Notably, it has also been shown that differences in N-cadherin distribution rather than in
its expression levels are responsible for different motility behaviours [64,65].
In addition, several studies showed that the treatment of primary GBMs with radiation therapy or
with the anti-angiogenic agents Bevacizumab promotes the acquisition of a mesenchymal phenotype
in recurrent tumors [34,66–68]. Indeed, glioma cells that have acquired radioresistant properties
following treatment exhibit a gene expression profile enriched for genes involved in EMT-related
processes [34,69,70], and the pathways promoting EMT result strongly upregulated in these cells,
thereby resulting in an increased invasion capability [71,72]. An in vivo study by Halliday et al.
demonstrated that proneural GBM cells rapidly shifted their gene expression pattern towards a
mesenchymal phenotype in response to radiation therapy in a tumor-bearing mouse model [66].
As radiation is a universal component in the treatment of GBMs, this subtype shift poses an important
clinical challenge, especially considering that cells shifted to a mesenchymal subtype display an
increased radioresistance [73]. If this shift is due to changes in the microenvironment or to clonal
selection of mutant therapy-resistant cells is controversial, but both the hypotheses seem to be possible.
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3. Autophagy
The term “autophagy” was coined by the discoverer of lysosomes Christian de Duve and it means,
in Greek language, “self-eating” [74–76]. From the first description of the process in 1960s, many
studies described the process of self-degradation by a morphological point of view, until in 1993 a
genetic screen led to isolation of some yeast autophagy-defective mutants and to identification of the
so-called AuTophaGy-related (ATG) genes [77]. This seminal work allowed Yoshinori Oshumi to be
awarded the Nobel Prize in Physiology and Medicine in 2016. Oshumi’s screen identified 15 genes
involved in autophagy regulation in yeast undergoing nutrient deprivation, but today, more than 40
genes have been described in yeast, many of them having orthologues in vertebrates [76]. Three main
types of autophagy have been described: macroautophagy, microautophagy and Chaperone-Mediated
Autophagy (CMA).
3.1. Mechanisms and Molecules
During macroautophagy (hereafter referred to as autophagy), double-membrane vesicles named
autophagosomes form and engulf cytoplasmic material, including long-lived proteins and old or
damaged organelles which are then delivered to lysosomes for degradation and recycling [78].
Always activated at basal level within the cell, autophagy can be modulated by several signals,
mainly by nutrient signaling, growth factors, energy status, oxidative or ER stress and pathogen
infection. The input from these upstream signals is integrated by the serine/threonine protein
kinase mTOR (mechanistic or mammalian target of Rapamycin), which acts upstream of the ATG
genes, thus controlling autophagy activation [79]. mTOR belongs to the phosphoinositide 3-kinase
(PI3K)-related kinase family, and, in mammalian cells, works as the catalytic subunit of two
multi-protein complexes known as mTORC1 and mTORC2 [80]. Under nutrient deprivation, mTOR is
inhibited and Ulk1/Atg13-FIP200 complex initates and drives a massive autophagy activation [81].
Autophagosome formation requires the formation of a multi-protein complex, composed by class
III PI3K, Beclin1 and p150, although other proteins such as UVRAG, Ambra1 and Atg14L are able
to bind and regulate the complex [82–86]. Elongation and maturation of autophagosomes involve
two ubiquitin-like conjugation systems, both requiring Atg7, which catalyze the covalent linkage of
ATG5 to ATG12 and ATG16-like 1, and the attachment of phosphatidylethanolamine to proteins of the
microtubule-associated protein 1 light chain 3 (MAP1LC3 or LC3) family [87].
Lipidated LC3 protein is then recruited to the autophagosome membrane that docks and fuse
with lysosome, resulting in the formation of a single membrane vesicle named autophagolysosome or
autolysosome. Lysosomal hydrolases, ultimately, degrade and recycle the content of autolysosomes.
Although originally suggested to be just a nonspecific and bulk degradation mechanism,
autophagy is now recognized as a highly regulated process, enabling cells to sense and promptly
respond to a plethora of stimuli, thereby conferring adaptation to the ever-changing environment.
Nevertheless, even though a basal level of autophagy contributes to maintain the proper cell
homeostasis both during embryogenesis and adulthood in physiological conditions, it is now
ascertained that autophagy is deregulated in various human pathologies, including cancer [88–90].
3.2. Autophagy Role in Tumorigenesis
The observation in 1999 that the gene encoding Beclin1 is monoallelically deleted in a high
percentage of human breast, ovarian and prostate cancers provided the first evidence of the
involvement of the autophagic process in tumorigenesis [91]. Disruption of Beclin1 in mice results in
an increased proliferation and in the spontaneous development of various malignancies, confirming
Beclin1 as an haploinsufficient tumor suppressor gene [92,93]. In a similar way, mice lacking one copy
of the Beclin1 interactor Ambra1 exhibit a higher incidence of spontaneous tumors than their wild type
littermates, and cells depleted of the gene are characterized by a hyperproliferative phenotype [94].
Notably, Ambra1 homozygous disruption in mouse leads to a strong hyperproliferation and lethal
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defects in the developing nervous system during embryogenesis [82]. Mice bearing systemic or
tissue-specific deletion of Atg5 and Atg7 also develop tumoral masses a higher frequency than the wild
type counterparts [95] and are more prone to develop cancers upon carcinogen-induced stimuli [96–98].
Several mechanisms have been proposed to explain the oncosuppressive functions of
autophagy [90]. First of all, the autophagy-mediated clearance of proteins and organelles ensures
the proper cellular homeostasis, avoiding the accumulation of genotoxic molecules, such as reactive
oxygen species (ROS) produced by dysfunctional mitochondria, as well as aggregates of ubiquitinated
proteins [99,100]. An intact autophagic machinery is also required to deal with cytotoxic stress
and to maintain genome stabilization, although further investigation is required to underlie the
mechanisms involved [101,102]. Moreover, autophagy counteracts the metabolic switch accompanying
malignant transformation by eliminating old and damaged mitochondria, thus preserving the optimal
bioenergetic needs and maintaining the physiological metabolic homeostasis [103,104].
Other potential mechanisms through which autophagy acts as an oncosuppressive process are
linked to its role in the regulation of immune response [105], maintenance of the staminal niches [106],
defens of the organism against pathogen infections and degradation of oncogenic proteins, like mutant
(but not wild-type) TP53 [107].
On the other hand, it is well accepted that, in an established tumor, cancer cells use autophagy
as a strategy to overcome microenvironmental stresses, including nutrient deprivation, hypoxia and
drugs. Advanced tumors sometimes exhibit an increased autophagic flux and ex-vivo cell lines in
which BECN1 or ATG5 have been down-regulated are virtually unable to survive within the metastatic
niche [108]. Analogously, autophagy-defective tumoral cells appear more sensitive to pro-apoptotic
stimuli than autophagy-proficient cells [109–112].
Due to this dual function, autophagy has been defined a ‘Janus-faced’ player in cancer
progression [113]: in the early stages of tumorigenesis it plays onco-suppressive functions by
limiting cell proliferation, DNA damage and tumor progression; on the contrary, when the
tumor mass is established, it helps cells to counteract the stressful conditions characterizing the
tumor microenvironment.
3.3. Autophagy and Glioblastoma: Friends or Foes?
It was demonstrated that high-grade gliomas exhibit lower expression of some autophagy related
proteins with respect to low-grade ones, and that the progression of astrocytomas toward higher
grades is accompanied by a decrease in autophagic proficiency. Pirtoli et al. observed that both
BECN1 mRNA (encoding for Beclin1) and protein levels are lower in GBM tissue than in low-grade
and healthy brain tissue [114]. Accordingly, following Karnofski classification, high Beclin1 levels
have been positively correlated with patient survival and performance status, whereas low Beclin1
expression correlates with an increase of proliferation [114]. Similarly to Beclin1 expression, also LC3B
II expression (index of autophagy activation) is low in high-grade astrocytomas, thus suggesting an
impairment of the autophagic process in these tumors [115]. On the other hand, in 2012, through a
proteomic screening, Galavotti et al. found that some genes involved in autophagy regulation are
highly expressed in the GBM mesenchymal subtype [116]. Among these, the autophagy associated
genes DRAM1 and SQSTM1 encoding for the key regulator p62 are highly expressed in Glioma stem
cells (GSCs), and modulate their migration and invasion capabilities [116]. Although these studies
suggest that autophagy may regulate gliomagenesis, a systematic and comprehensive investigation of
autophagy role among the GBM subtypes is missing, but needed. Indeed, a different expression of
autophagy regulators across GBM genetic groups could be responsible for a different susceptibility to
autophagy modulation.
In addition to the growing evidences showing a direct involvement of autophagy-regulating
genes in GBM progression, several autophagy-associated molecules are frequently altered in brain
tumors. As an example, the tyrosine kinase EGF receptor is often amplified in gliomas, and suppresses
autophagy through both kinase-dependent and -independent mechanisms [117]. PTEN, is commonly
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mutated in gliomas, and positively regulates autophagy by inhibiting the PI3K/Akt pathway, although
PTEN and NF1 co-mutation determines an autophagy suppression through the hyperactivation of the
PI3K/Akt signalling [118].Furthermore, the oncosuppressor p53, frequently mutated in gliomas, may
have a dual role in autophagy regulation, as the nuclear protein is able to promote autophagy through
the transcriptionally regulation of autophagy-related genes, whereas cytoplasmic p53 suppresses
autophagy [119]. Further investigation are needed to define whether autophagy machinery may be
considered as a novel useful prognostic and/or therapeutic marker of glial tumors.
4. Autophagy and Epithelial-to-Mesenchymal Transition
Autophagy was only recently connected to EMT. In the last years, some observations indicated that
an intricate relationship exists between these two important processes in cancer [120]. According to
its dual role in tumorigenesis, the effect of autophagy on EMT appears controversial and strictly
dependent on the cellular type and on the stimulus employed for activating or inhibiting autophagy,
as summarized in Table 2 and in Figure 1.
Literature data highlights that an autophagy stimulation of metastatization could be merely
the consequence of its pro-survival activity against the apoptotic signals coming from changes in
adhesion and cytoskeleton reorganization [108]. A number of compounds or microenvironmental
conditions that are able to activate the EMT programme, can also induce an autophagic response
in different types of cultured cancer and non-cancerous cells; autophagy inhibition in these models
impairs EMT (Table 2).
However, emerging evidence also indicates that autophagy activation can induce a reversion of
the EMT phenotype in different healthy and cancer models and that several anticancer compounds that
induce autophagy also inhibit EMT [121–123] (Table 2). Selective degradation of EMT players seems
to be a general mechanism by which autophagy can modulate EMT process [124]. Notably, in ATG3,
ATG5, ATG9 and ATG12 KO mice, p62 accumulation accumulation determines stabilization of Twist1,
which is normally degraded by both proteasome and autophagosomes [125]. This regulation can be
crucial in those tumors characterized by p62 up-regulation, as observed so far in human squamous
cell carcinoma and in melanoma (Table 2). Autophagy deficiency reduces the expression of epithelial
markers and increases that of mesenchymal ones also in ATG7 KO hepatocytes [126] (Table 2).
Table 1. Autophagy and EMT.
Cell/Tissue Autophagy Modulation Effect on EMT on EMT Mechanism References
HCC cells
Induction by starvation




















Ovarian cancer cells Induction by Danutreatment Inhibition unknown [123]
Non tumorigenic
hepatocytes
Induction by starvation +
TGF β1







NPC cells Induction by Cisplatin Induction unknown [132]
NSCL cells Induction by TGFβ1treatment Induction unknown [133]
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Table 2. Autophagy and EMT.




co-colture Induction Snail up-regulation [134]
Endometrial cells Induction by Hypoxia Induction unknown [135]





Kidney podocytes Inhibition by V-ATPase Inhibition Reduction of p62phosphorylation [138]
MEFs, keratinocytes,
melanoma cells Inhibition by ATG KD Induction
p62-mediated Twist
stabilization [139]
Breast Activation by DEDDoverexpression Inhibition Snail and Twist degradation [140]
Gastric cancer cells
and tissue Inhibition by BECN1 KD Inhibition
ROS-NFκB-HIF-1α pathway
activation [141]
3-MA, 3-methyladenine; ALS, Alisertib (Aurora kinase A inhibitor); ATG, autophagy related gene; Baf, bafilomycin;
BECN1, Beclin1; cAMP, cyclic adenosine monophosphate; CQ, chloroquine; CREB, cAMP responsive element
binding; Danu, Danusertib; DBP, n-butyl phthalate; DEDD, death effector domain containing; DRAM1, DNA
damage-regulated autophagy modulator 1; EMT, epithelial to mesenchymal transition; HCC, hepatocarcinoma
cells; HIF-1α, hypoxia-inducible factor 1; KD, knockdown; MEFs, mouse embryonic fibroblasts; MSC, mesenchymal
stem cell; NF- κB, nuclear factor kappa beta; NPC, nasopharyngeal carcinoma; NSCL, Non-small cell lung;
PI3KC3, phosphatidylinositol 3-kinase; PKA, protein kinase A; Rac1, Ras-related C3 botulinum toxin substrate
1; RhoA, Ras homolog gene family, member A; ROS, reactive oxygen species; Smad3, small mother against
decapentaplegic3; SQSTM1, sequestosome 1; TGFβ, Transforming growth factor beta; V-H-ATPase, vacuolar-type
H+-adenosine triphosphatase.
Taken together, these observations show a complex crosstalk between autophagy and EMT processes.
It is conceivable that, at the early stages of metastatization, autophagy acts as oncosuppressive signal,
tending to inhibit the EMT programme mainly by destabilizing EMT crucial players. Later on, metastatic
cells could require a sustained autophagy to survive to environmental and metabolic stressful
conditions encountered [113].
4.1. Autophagy Role on Glioblastoma Dissemination
To date, only a few studies correlate autophagy to GBM cells capability to migrate and spread
toward surrounding tissues, and, similarly to what observed in other tumor models, they highlight
two opposite point of views, as detailed below, in Section 4.1.1, and as illustrated in Figure 1.
4.1.1. Autophagy Promotes Glioblastoma Dissemination
In 2012, Galavotti et al. showed that some autophagy players are up-regulated in GBM
mesenchymal subtype, and that their modulation modifies the migration properties of GBM cells.
They observed that GSCs require autophagy activation to migrate, and down-regulation of the
autophagy-associated factors DRAM1, p62 and ATG7 limit their invasion capabilities potentially
through the regulation of energy metabolism [116] (Figure 1A). In line with these observations, a study
conducted by using an 3D organotypic model of GBM showed that ATG12 RNA silencing reduced
cellular invasion, although no modifications of cellular migration capabilities was observed [142]
(Figure 1A). More recently, another couple of studies have correlated autophagy activation induced by
a combination of different stimuli with an enhanced mesenchymal phenotype in GBM cells through
various mechanisms [143,144]. Lastly, inhibiting the late stages of autophagy by using Chloroquine,
Liu et al. showed a potentiation of the effect of the multi kinase inhibitor Sorafenib in reducing cell
proliferation and migration, through a further stimulation of apoptosis [145] (Figure 1A).
4.1.2. Autophagy Impairs Glioblastoma Dissemination
In spite of the previous mentioned evidence, we and other groups have recently demonstrated a
direct effect of autophagy modulation on migration and invasion capabilities of GBM cells, as illustrated
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in Figure 1B. Autophagy induction by nutrient deprivation or by mTOR inhibition determines a
reversion of EMT phenotype in immortalized and primary GBM cells [146–149]. In 2014, Palumbo
et al. observed that ATG7 RNA silencing restored clonogenic ability of irradiated GBM cells with
inactive EGFR and, conversely, that rapamycin-mediated autophagy further impaired their clonogenic
and migration capabilities [148]. Later on, we demonstrated that autophagy induction in GBM
immortalized and primary cells, obtained by nutrient starvation or by mTOR pharmacological
inhibition, induced a drastic impairment of both migration and invasiveness. On the contrary,
autophagy deficiency, obtained by silencing the autophagy master genes ATG5, ATG7 or BECN1,
stimulated cell motility [146], similarly to what observed in highly metastatic breast, colon and
hepatocellular cancer models [122,124,130]. We correlated the migration properties of the cells
analyzed with a molecular shift from a mesenchymal to an epithelial-like phenotype (Figure 1B).
Upon autophagy induction, in fact, we found a down-regulation of the EMT players Snail and
Slug, likely due to a general impairment of protein synthesis mediated by mTOR inhibition, rather
than to the autophagosome-mediated degradation [146]. As an outcome of SNAI down-regulation,
the up-regulation of N- and R-cadherin mRNA and protein expression was observed, whereas no
significant differences in other cadherin family members were found (Figure 1B). Remarkably, as
above discussed, although a “cadherin shift” from the E- to the N- isoform is actually believed a
hallmark of carcinoma cells undergoing EMT, the role of cadherins in non-epithelial tumors is much
less documented and elucidated. N-cadherin overexpression or re-distribution has been associated
with the recovery of the cell polarity and the inhibition of migration of GBM cells [62–65]. Notably, we
have recently found that, upon autophagy induction, the Wnt signaling effector β-catenin relocalises
within the cell and associates to N-cadherin in sub-membrane compartments to form epithelial-like
cell-cell adhesion structures [147], thus contributing to a mesenchymal-to-epithelial-like transition of
GBM cells (Figure 1B). Similarly to other tumors, Wnt pathway is constitutively active in GBM and its
deregulation is likely responsible for initiation and/or progression of the disease [150–153]. β-catenin
translocation to the nucleus characterizes the mesenchymal and invasive phenotype of tumoral cells as
it promotes SNAIL and ZEB1 transcription and mediates EGFR pathway-induced EMT [154–156].
In summary, a complicated interplay between autophagy process and EMT/MET activation in
GBM is recently emerging. Contradictory results could be explained by the different stimuli and
different models employed. Notably, autophagy induction obtained through mTOR inhibition or
nutrient deprivation always results in migration/invasion reduction in independent experiments and
different GBM cell lines. Conversely, autophagy activation resulting by the employment of drugs like
TMZ plus low glucose, or by TGF-β, or by AEG overexpression is associated to promotion of migration
capabilities of GBM cells, maybe suggesting that different and complex mechanisms contribute to the
migratory phenotype in those contexes.
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next section. More controversial, although conducted in different model systems, are the results on
GBM invasiveness obtained by inactivating ATG genes. In light of such contradictory results, further
in-depth investigation is, for sure, required to better unravel the question.
4.2. Targeting Autophagy in Glioblastoma Therapy
In the last decade, the standard therapeutic regimen for GBM has been surgical resection, if
feasible, followed by radiation therapy (IR) and temozolomide (TMZ)-based chemotherapy. Both
TMZ and IR are able to induce an autophagic response in GBM cell lines, likely through DNA
damage induction, but the outcome of the autophagic response is so far inconclusive (Figure 2).
In 2004, Kanzawa et al. reported that TMZ treatment induced autophagy instead of apoptosis in
GBM cells and that the co-treatment with a pharmacological inhibitor of the late stages of autophagy
restored TMZ-induced cytotoxicity, although the opposite effect was obtained by blocking autophagy
initiation [157]. In line with this observation, the combination between standard therapies and
autophagy flux inhibitors Chloroquine (CQ) or its analog hydroxychloroquine (HCQ) is a promising
therapeutic approach in GBM treatment, and combined therapies including these molecules are
currently employed in ongoing phase III clinical trials (Figure 2). Indeed, CQ and its derivatives are, in
fact, the only autophagy inhibitors already approved by the USA Food and Drug Administration due
to their anti-inflammatory and anti-malarial properties. Similar to other tumoral settings, CQ-treated
GBM patients exhibit a better median survival if compared to placebo-treated individuals [158].
However, despite the potential promising beneficial effect, a trial combining HCQ with TMZ and IR
showed that the maximum tolerated HCQ dose was ineffective in inhibiting autophagy, suggesting
that CQ effect could be due to autophagy-independent mechanisms [159]. Notably, it has been recently
shown that, in addition to DNA intercalation properties and ROS production, CQ also induces a strong
autophagy-independent disorganization of the Golgi apparatus and of the endo-lysosomal system in
mice tissues, thus suggesting caution in interpreting results obtained with this drug [160,161].
In an apparently contradictory way, other therapeutic approaches and clinical trials aimed
at inhibiting mTOR pathway, inducing in turn an autophagic response, have been launched.
PI3K/Akt/mTOR pathway is often deregulated in human cancers including GBM, and is involved in
cancer stem cell maintenance, thus inducing an uncontrolled proliferation [162,163]. It was observed
that the co-treatment of TMZ and the mTOR inhibitor RAD001 (also known as everolimus) induced cell
death [164] (Figure 2). RAD001 was shown to enhance the cytotoxic effect of an oncolytic adenovirus
in a viral-mediated therapy by inducing an autophagy-dependent cell death [165,166].
mTOR inhibition also promotes TMZ-induced senescence in in vitro and in vivo models [167,168].
However, the link between autophagy and senescence needs to be further clarified in order to be
exploited a potential therapeutic tool.
Very recently, it has been suggested that the failure of some clinical trials targeting PI3K and mTOR,
could be due to the employment of Rapalogs (rapamycin and its analogs) which are known to inhibit
mTORC1, but not mTORC2 [149]. In fact, a feedback mechanism activated by mTORC1 inhibition
stimulates mitogenic pathways, thus compromising the rapalog efficacy on cell proliferation [169].
In order to overcome the emerged limitations, a second generation of mTOR inhibitors, (named
ATP-competitive mTOR kinase inhibitors or TORKIs) have been developed and are revealing more
efficacious than rapalogs in GBM treatment [170–172]. As an example, the novel TORKI PP242, able to
target both mTORC1 and mTORC2, impairs cell proliferation and reduces stemness and invasiveness
properties in a group of GBM cell lines carrying different genetic alterations [149] (Figure 2). In this
respect, a putative difference in the “autophagy signature” among GBM subtypes, if found, could
affect the response to the treatments.
Notably, in our model, we have obtained β-catenin relocalisation and migration impairment by
both nutrient deprivation and by inhibiting mTOR complexes by means of Torin 1, an ATP-competitive
mTOR inhibitor able to target both the mTOR complexes [147].
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Finally, a number of compounds, such as arsenic trioxide, sodium selenite and cannabinoids
(THC), used in combination with traditional therapy showed beneficial effects through the induction
of an autophagic response, in some cases potentiating drug-induced cell death, some other inducing
mitochondrial damage or ER stress [173–176] (Figure 2). In addition, autophagy-induced cell death
seems also to be the mechanism by which some compounds overcome the apoptosis-resistance
typical of the anoxic cells inside tumors. For instance, the class of small molecules able to bind the
BH3 domain of the anti-apoptotic protein Bcl-2, known as BH3 mimetics, were found to induce an
autophagy-dependent cell death in GBM [177,178]. If these compounds are also able to trigger a
beneficial or detrimental effect on GBM invasiveness remains to be investigated.
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5. Concluding Remarks 
GBM is the most common and aggressive brain malignancy, and is characterized by a highly 
invasive behaviour, although the role of EMT in GBM dissemination has only been recently 
investigated. Although several molecules and signalling pathways mediating EMT in carcinomas 
play a role also in glioma invasion, further investigation will be necessary to better characterize EMT-
like and its reverse MET-like processes occurring in GBM. 
Targeting autophagy in GBM therapy is still a matter of debate; autophagy induction has been 
observed in GBM in response to radio- and temozolomide-based therapy and even though a number 
of clinical trials aimed at inhibiting autophagy execution, mainly by CQ, have been launched, others 
directed to inhibiting mTOR pathway, and thus activating autophagy, are ongoing. 
Intriguingly, we observed that autophagy induction by nutrient starvation or by mTOR 
inhibition impairs migration and invasion of GBM cells, in line with other studies conducted on other 
cancer models. Further in-depth studies will be crucial to clearly dissect the autophagy role in GBM 
biology and to carefully evaluate autophagy modulation as therapeutic strategy to contrast GBM 
progression. 
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therapy) impairs the autophagy flux and sensitizes GBM to the treatment (pink box). Otherwise,
several chemical compounds and mTOR inhibitors, that are able to stimulate autophagy, also increase
the efficacy of the standard treatments (green boxes). THC, tetrahydrocannabinol.
5. Concluding Remarks
GBM is the most common and aggressive brain malignancy, and is characterized by a highly
invasive behaviour, although the role of EMT in GBM dissemination has only been recently investigated.
Although several molecules and signalling pathways mediating EMT in carcinomas play a role also in
glioma invasion, further investigation will be necessary to better characterize EMT-like and its reverse
MET-like processes occurring in GBM.
Targeting autophagy in GBM therapy is still a matter of debate; autophagy induction has been
observed in GBM in response to radio- and temozolomide-based therapy and even though a number
of clinical trials aimed at inhibiting autophagy execution, mainly by CQ, have been launched, others
directed to inhibiting mTOR pathway, and thus activating autophagy, are ongoing.
Intriguingly, we observed that autophagy induction by nutrient starvation or by mTOR inhibition
impairs migration and invasion of GBM cells, in line with other studies conducted on other cancer
models. Further in-depth studies will be crucial to clearly dissect the autophagy role in GBM biology
and to carefully evaluate autophagy modulation as therapeutic strategy to contrast GBM progression.
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Abstract 
EGFR is a tyrosine kinase receptor widely expressed on the surface of numerous cell types, which 
activates several downstream signalling pathways involved in cell proliferation, migration and 
survival. EGFR alterations, such as overexpression or mutations, have been frequently observed in 
several cancers, including glioblastoma (GBM), and are associated to uncontrolled cell proliferation. 
Here we show that mTOR inhibition mediates EGFR internalization and delivery to lysosomes for 
degradation in GBM cells, independently from autophagy activation. Accordingly to EGFR 
internalization and degradation, mTOR blockade negatively affects MAPK/ERK pathway. 
Furthermore, we provide evidence that Src kinase activation is required for EGFR internalization 
upon mTOR inhibition. Our results confirm the hypothesis that mTOR could be an effective target in 
GBM pharmacological treatment, as its inhibition could result in EGFR degradation and in 
proliferative signal alteration. 
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Epidermal Growth Factor receptor (EGFR), also known as ErbB1 or HER1, belongs to the tyrosine 
kinase receptors family (RTK) and regulates epithelial tissue development and homeostasis (1). In 
physiological conditions, inactive RTK receptors continuously travel through the endocytic 
compartment, slow internalization and recycling to plasma membrane. EGF binding stimulates EGFR 
activation and signal transduction inside the cell, thus regulating cell growth, differentiation, 
proliferation and migration (2,3). In particular, upon ligand engagement, activated receptors are 
subjected to clathrin-mediated (CME) or clathrin-independent (CIE) endocytosis in dependence on 
ligand abundance, and spend most of their remaining lifetime travelling the vesicular network of 
endosomes (4–8). Once internalized in early endosomes, EGFR can be recycled to cell surface or 
delivered to lysosomes for degradation, in a delicate balance between continuous signalling from cell 
surface/endosomal compartments and signal attenuation from the degradative route (4,9).  
It has been demonstrated that activated RTK still retains the ability to continuously signal within the 
vesicular compartments until the receptors are recycled back to cell surface or taken up into lysosomes 
for degradation (9).  
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EGFR alterations have been reported in several diseases, particularly, in cancer (10). Indeed, EGFR 
gene is frequently mutated, amplified or overexpressed in various kinds of tumours including 
Glioblastoma multiforme (GBM), the most aggressive brain tumor in adults (10,11). In particular, in 
GBM EGFR is amplified in 40%, overexpressed in 60% and mutated or deleted in 24-67% of primary 
tumors (12). Deletion of exon 2-7, also known as variant III (EGFR vIII), represents the most 
frequently occurring mutation in GBMs, found in up to 45% of cases (13,14). Mutated EGFR are 
usually constitutively active, ligand-independent receptors with an altered trafficking and down-
regulation, resulting in an aberrant downstream signal transduction which promotes tumour 
development (15,16). Receptor overexpression, which is often associated to an enhanced expression 
of cognate ligands (17), is also associated to receptor turnover alterations and to increased 
downstream signalling (18,19). mTOR kinase is part of two multi-protein complexes, known as 
mTORC1 and mTORC2, that acts as nutrients sensors in the cell, regulating protein synthesis through 
a phosphorylation cascade (20). Aberrant mTOR activation is linked to tumour proliferation and 
invasion. For this reason, mTOR protein is recurrently proposed as a putative pharmacological target, 
and several specific inhibitors, mainly directed to mTORC1, have been developed and tested in the 
last decade (21). mTOR also regulates autophagy, a lysosome-degradation system crucial to maintain 
cellular homeostasis (22). As nutrients sensor, mTOR is normally activated under fed conditions, 
leading to autophagy inhibition; conversely, nutrient starvation results in mTOR inactivation and in 
a subsequent autophagy induction.  
It is now well established that RTK signalling regulates PI3K/mTOR pathway and autophagy. 
However, the possible existence of an opposite relation has still not been investigated (23). In this 
work, we evaluated the prospective modulation of mTOR on EGFR activity and turnover. We found 
that mTOR inhibition delocalises EGFR from plasma membranes to the cytoplasm in GBM cellular 
models. We also observed that the receptor is delivered to lysosomes for degradation, independently 
of autophagy. These events ware also accompanied by the suppression of MAPK/ERK pathway, 





2.1 mTOR inhibition induces EGFR relocalisation in GBM cells 
Similarly to other tumors, GBM is characterized by an aberrant EGFR expression and activation, 
leading to de-regulated downstream signalling pathways. In order to investigate a putative impact of 
autophagic stimuli on EGFR expression and signalling in GBM, we cultured U87MG and GL15 cells 
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in EBSS (aminoacid- and serum- free medium) or in presence of Torin1 and AZD8055, two inhibitors 
of both mTORC1 and mTORC2 complexes, for 18 hours. GH2 primary cells were also cultured in 
complete medium or in presence of Torin1 for 18 hours. As shown in figure 1A (left panels), mTOR 
inhibition obtained by cell exposure to the different treatments, was confirmed by the strong decrease 
of the phosphorylated forms of its substrate P70S6K, observed by western blotting analysis. Next, 
we checked for EGFR subcellular localisation by immunocytochemistry and we found, as expected, 
the receptor mainly localized at plasma membrane of control cells; conversely, autophagic cells did 
not show EGFR membrane exposure (Figure 1A, right panels). Chiefly, EGFR signal was strongly 
reduced 18 hours after EBSS treatment, whereas a punctate immunostaining pattern was observed in 
discrete areas within cytoplasm in Torin1 and AZD8055-treated cells (Figure 1A, right panels). A 
time-course analysis revealed that EGFR re-localization was already evident in 2 and 4 hours after 
mTOR inhibition with Torin1 (Fig. 1B). 
 
2.2 EGFR de-localization is not dependent on canonical autophagy in GBM cells 
In order to discriminate between an autophagy-dependent or -independent effect of mTOR inhibitors 
on EGFR de-localization, a Beclin1-silenced GL15 cell line was employed (24). GL15 shBeclin1 are 
not able to accumulate LC3II (the autophagosome-associated form of LC3) and to degrade the 
autophagy substrate P62, two autophagy hallmarks (25), in both basal and starved conditions, being 
Beclin1 indispensable for canonical autophagy (Figure 2A, left panel and (26)). Interestingly, Beclin1 
silencing did not prevent EGFR de-localization upon EBSS incubation or upon Torin1 treatment for 
18 hours (Figure 2A, right panels). To confirm an autophagy-independent role of mTOR on EGFR 
trafficking, we infected U87MG cells with a GFP-LC3 expressing retrovirus and analyzed EGFR 
localization upon autophagy stimulation. Immunofluorescence analysis shows the appearance of the 
typical GFP-LC3 dots, identifying autophagosomes, 24 hours after Torin1 treatment (Figure 2B). 
Notably, GFP-LC3 puncta did not co-localize with EGFR intracellular signal in Torin1-treated cells, 
thus excluding a re-localization of the receptor within autophagosomes (Figure 2B). These results 
indicate that mTOR activity is involved in EGFR internalization and trafficking, independently of its 
role on autophagy regulation. 
 
2.3 mTOR inhibition targets EGFR to lysosomes 
Next we investigated the subcellular compartment involved in EGFR translocation mTOR inhibition. 
To this aim, we performed immunofluorescence analyses by using specific subcellular markers for 
cytoplasmic organelles, that hare known to be involved in RTK trafficking (4).  
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Figure 3 A-C shows that EGFR signal is largely separated by those of endoplasmic reticulum, Golgi 
cisternae and mitochondria upon mTOR inhibition in U87 cells. By contrast, a great amount of EGFR 
was detected in correspondence to CathepsinD-positive puncta, indicating a lysosomal delivery of 
the receptor upon 24 hours following Torin1 treatment (Figure 3D). The occurrence of EGFR 
localization to lysosomes upon Torin1 administration was also observed in GL15 cells and in primary 
GH2 cells (Suppl. Figure S1). 
 
2.4 EGFR expression is reduced upon mTOR inhibition in GBM cells 
The obtained results prompted us to verify whether the mTOR inhibition could produce any effects 
on EGFR protein expression. Thus, we analysed the expression level of the receptor in U87MG and 
GL15 cells cultured in presence or not of Torin1. Western blotting analysis indicated a significant 
reduction of EGFR expression in 2 and 4 hours of Torin1 exposure (Figure 4A) which persisted up 
to 24 hours (Figure 4B), compared to control cells. Likewise, the reduction of EGFR protein levels 
was also observed in primary GH2 cells treated with Torin1 for 2, 4 and 24 hours (Figure 4C). These 
results suggest that the mTOR inhibition induces EGFR degradation, in line with the observation of 
EGFR lysosomal delivery.   
 
2.5 mTOR inhibition leads to MAPK/ERK pathway down-regulation in GBM cells 
EGFR is involved in cell proliferation, growth and differentiation, through the activation of several 
downstream signal transduction pathways, including MAPK/ERK cascade. Therefore, we checked 
whether the EGFR de-localization and degradation occurring upon mTOR inhibition also affected 
ERK activity. To this aim, U87MG and GL15 were grown or not in presence of Torin1 at different 
time points, and western blotting analyses was performed, by taking advantages of antibodies 
recognizing the phosphorylated, activated, forms of ERK1/2. As shown in figure 5A, ERK1/2 
phosphorylation was strongly and persistently suppressed in Torin1-treated cells, being observable at  
2 and 4 hours after treatment, and maintained up to 48 hours compared to control cells. ERK1/2 
dephosphorylation was maintained up to 48 hours in U87MG and in GL15 (Figure 5B). Moreover, 
the dependence of ERK modulation on mTOR inhibition was further evaluated in GBM primary cells. 
Similarly to U87MG and GL15 cells, ERK1/2 activation was drastically reduced after 2 and 4 hours 
following Torin1 treatment, although it increased again after 24 hours exposure (Figure 5C). 
 
2.6 SRC activity is required to EGFR internalization in GBM cells 
RTK endocytosis is regulated by clathrin-dependent and -independent mechanisms. It has been 
shown that Src kinase plays a role in regulating EGFR endocytosis by phosphorylating clathrin heavy 
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chain following EGF binding to receptor (27,28). Thus, we checked whether Src activity was 
involved in EGFR internalization upon mTOR inhibition. First, we performed western blotting 
analysis by using an antibody raised against the phosphorylated and active form of Src on protein 
extracts of U87MG stimulated or not with EBSS, Torin1 or AZD8055 for 18 hours. As shown in 
Figure 6A, mTOR inhibition resulted in Src activation upon exposure to all the mTOR-inhibitory 
stimuli employed in this study. Src activation was already evident after 6 hours of Torin1 treatment, 
and was completely prevented by co-administration of Src inhibitor PP2 (Figure 6B). Notably, EGFR 
internalization was completely abrogated when cells were incubated with PP2 for both 6 and 24 hours, 




EGFR is one of the most studied RTK members due to its well-known oncogenic activity (10). For 
the same reason, during last decade, it has emerged as powerful target of multiple cancer therapies, 
some of them successfully introduced in clinical practice for some tumours type. A specific group of 
EGFR deletions, point mutations and amplification are frequently found in GBM (29). Specifically, 
overexpression of this receptor on the cell surface is found in 60% of primary GBM, and is associated 
with the most aggressive GBM phenotypes (12). Overexpression and oncogenic mutations of EGFR 
lead to spontaneous dimerization and activation of the receptor, independently on the presence of the 
ligand (30). In addition, beside abnormal expression and activation, dysregulated EGFR intracellular 
trafficking also plays a crucial role in GBM oncogenesis (9).  
For the first time we demonstrated that the inhibition of the mTOR complexes obtained by drug 
administration or by aminoacid depletion strongly induces EGFR disappearance from the plasma 
membrane and its internalization within GBM cells. Receptor delocalization was still observed in 
cells defective for the autophagy master gene BECLIN1, thus suggesting that autophagy induction is 
not responsible for EGFR de-localization.  
Besides the well-characterized recycling and degradative trafficking pathways, emerging evidence 
underlies alternative routes for EGFR endocytosis, including traffic to nucleus, mitochondria and 
other subcellular compartments (31,32). We did not found any co-localization with nucleus, 
mitochondria, ER and Golgi, whereas a strong overlapping signal was observed into lysosomes. 
EGFR positivity was not observed into autophagosomes, thus confirming that receptor delivery to 
the degradative compartment is not mediated by the autophagic network. An evident decrease in 
protein expression supports the evidence that mTOR blockade impairs receptor recycling and directs 
EGFR to the degradative route. This observation is in line with literature data demonstrating that 
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mTOR activity is necessary for the recycling route of Transferrin receptor and plasma membrane 
lipids (33). Indeed, mTORC1 inactivation reduces the expression of hepatocyte growth factor-
regulated tyrosine kinase substrate (Hrs), a component of Endosomal Sorting Complex Required for 
Transport (ESCRT), which is crucial for lysosomal targeting of ubiquitylated cargoes (33). This event 
leads to transferrin receptors and sphingomyelin delivery to lysosomes, independently of canonical 
autophagy. 
In physiological conditions, EGFR phosphorylation at the plasma membrane leads to the recruitment 
of multiple effector proteins via recognition and binding of Src homology 2 (SH2) and 
phosphotyrosine-binding (PTB) domains to phosphotyrosine motifs on the receptor. Formation of the 
EGFR signaling complex, in turn, triggers a variety of signaling cascades involved in cell 
proliferation, migration, and survival. Interestingly, similar substrates are activated downstream of 
wt EGFR and EGFRΔIII, but with differing levels of intensity (13). These pathways include the 
phosphoinositide 3 kinase (PI3K), mitogen activated protein kinase (MAPK), signal transducer and 
activator of transcription 3 (STAT3) pathways and the non-receptor tyrosin kinase Src (17). In the 
tumoral masses, receptor alteration and impaired degradation are often associated to enhanced 
downstream oncogenic signaling (34,35). As a consequence of EGFR endocytosis and degradation, 
we observed a clear and rapid inhibition of ERK1/2 kinases activity in our models, thus suggesting a 
restriction of the proliferative potential of GBM cells. We also found that mTOR inhibitions elicits 
EGFR endocytosis by enhancing Src activation, as the administration of the Src inhibitor PP2 impairs 
the receptor internalisation when mTOR activity is suppressed. Src kinase is thought as a crucial 
partner for EGFR in mediating oncogenesis, as they co-localize in lipid rafts and synergize to increase 
the mitogenic activity of EGFRs (36,37). It has been also demonstrated that Src activity is required 
for clathrin phosphorylation and EGFR endocytosis upon EGF stimulation (27). Our results show 
that Src activity is positvily regulated by mTOR kinase in GBM cells and indicate a crucial role for 
mTOR/Src axis on EGFR trafficking and localization. 
 
4. Material and methods 
 
4.1 Cell culture 
Human glioblastoma GL15 cells were kindly provided by Dr. E. Castigli, University of Perugia, Italy. 
Glioblastoma patient-derived culture GH2 as obtained from human GBM tumour samples from the 
Spanish National Cancer Center (CNIO, Madrid, Spain) biobank (GH2). Histopathological typing 
was done according to the WHO criteria resulating as grade IV. All procedures involving samples of 
human origin were performed with the approval of the corresponding ethical committees from each  
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institution as well as of the ethical committee of Complutense University (Madrid, Spain). Briefly, 
GICs cultures were obtained by using the following procedure: tumour samples were mechanically 
and enzymatically dissociated with 0.12 mg/ml of collagenase type Ia from Clostridium histolyticum 
(#C9722, Sigma) for 2 hours at 37 ºC and filtered using a 100 µm nylon filter (Millipore, Burlington, 
MA, USA).  Cells were then plated and maintained as non-adherent neurospheres for at least 3 
consecutive passages (with the aim of enriching the cultures in cells with stem-like properties) in a 
DMEM:Ham’s  F-12  media  (Lonza,  Basel,  Switzerland) supplemented  with  1%  penicillin– 
streptomycin (Lonza), 5 mM HEPES buffer (Lonza), 2 mM ultraglutamine (Lonza), 20 ng/ml EGF 
and FGFb (Gibco, Carlsbad, USA), 2 µg/ml heparin sodium salt (Sigma), 1% B27 (Invitrogen, 
Carlsbad, USA) and 1 µg/ml    leukemia inhibitory factor (LIF, Millipore). 
Human U87MG and GL15 were cultured in DMEM (Lonza, Basel, Switzerland), supplemented with 
10% heat-inactivated FBS (Euroclone, Milan, Italy) and 1% penicillin/streptomycin solution 
(Euroclone, Milan, Italy). Cells were grown at 37 °C in a 5% CO2 humidified atmosphere. 
shBECLIN1 and shCTR cells were prepared by lentiviral infection as previously described (24). 
U87MG were infected by incubation with the supernatant of GFP-LC3-expressing retroviruses for 
8h in presence of 4 μg/ml poly-brene (38). 
For autophagy induction and mTOR inhibition, cells were cultured in Earle's Balanced Salt Solution 
(Sigma Aldrich) or in presence of 250 nM Torin 1 (Sigma Aldrich), or 100 nM AZD8055 (Sigma 
Aldrich). For SRC kinase inhibition, 20 µM PP2 (Sigma Aldrich) was added to the culture medium. 
 
4.2 Cell lysis and Western blotting 
Protein extracts were prepared by lysing cells with the appropriate amount of RIPA Buffer (50 Mm 
Tris HCl pH 7,4, Triton 1%, Na Deoxycholate 0,25%, SDS 0,1%, 150 mM NaCl, 1 mM EDTA, 5 
mM MgCl 2 supplemented with protease inhibitors cocktail). After incubation on ice for 30 min, 
samples were centrifuged at 16,000 g for 30 min. Supernatants were recovered and protein 
concentrations were determined using Lowry protein assay (Bio-Rad, Hercules, CA, USA). Proteins 
were separated by means SDS-PAGE and then electroblotted onto nitrocellulose (GE Healthcare, 
Life Sciences, Little Chalfont, Buckinghamshire, UK).  After blocking, membranes were incubated 
with primary antibodies diluted in PBS/5% non-fat dry milk/0,1% Tween-20 overnight at 4°C. 
Detection was obtained by using horseradish peroxidase-conjugated secondary antibody (Bio-Rad 
Laboratories, Milan, Italy) and visualized with ECL plus (GE Healthcare, Life Sciences, Little 
Chalfont, Buckinghamshire, UK). The following primary antibodies were used: anti- P-p70SK, anti- 
p70SK, anti- P-mTOR, anti- mTOR, anti-LC3B, anti- P-ERK1/2, anti- ERK1/2, anti- Src, anti- P-Src 
(Y416) (Cell Signaling, Danvers, MA, USA), anti-p62, anti-BECLIN1, anti-HSP90 (Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA), anti-EGFR (Upstate Biotechnology, USA), anti-β-Actin 
(Sigma Aldrich, Milan, Italy). 
 
4.3 Immunocytochemistry and confocal analysis 
Cells were grown on coverslips and fixed with 4% PFA in PBS, followed by permeabilization with 
0.1% Triton X-100 in PBS. EGFR (Upstate Biotechnology, USA), Calnexin, Tomm-20, Cathepsin-
D (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and Giantin (Abcam, Cambridge, UK) primary 
antibodies were incubated overnight at 4 °C and visualized by means of Alexa Fluor secondary 
antibodies (Invitrogen, Carlsbad, CA, USA). 
After nuclear staining with Hoechst 33342 (Invitrogen, Carlsbad, CA, USA), coverslips were 
mounted in antifade (SlowFade; Invitrogen, Carlsbad, CA, USA) and examined under a confocal 
microscope (TCS SP8; Leica, Wetzlar, Germany), equipped with a 40 × 1.40–0.60 NA HCX Plan 
Apo oil BL objective at RT. 
Co-localization was assessed by calculating the Pearson's correlation coefficients of at least 10 cells 
analyzed in three independent experiments. The Pearson's correlation coefficient was expressed as 
mean ± SD.  
 
4.4 Statistical analysis 
All experiments were performed at least three times. Sigma Plot software was used for statistical 





In our previous works, we demonstrated that nutrient starvation and mTOR inhibition strongly 
impaired EMT process and Wnt/β-catenin signalling in GBM cells, through β-catenin colocalisation 
with N-cadherin in sub-membrane areas (24,26,39). Here, we provide the first evidence for an 
involvement of mTOR/PI3K pathway in RTK trafficking and expression, thus enforcing the proof of 
concept that mTOR complexes may be considered as potential tools for pharmacological 
interventions in cancer, including GBM (40).  
EGFR is currently considered a promising therapeutic target in cancer treatment; since its alterations 
show an homogenous and tissue-specific distribution across the tumour mass and are scarcely 
detectable in the healthy brain and in other tissues, making it an attractive target for therapeutic 
intervention. In this context, the clinical benefits of EGFR inhibitors have been observed in some 
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kinds of tumour. For instance, both monoclonal antibodies and EGFR-directed inhibitors are 
employed and continuously optimized as antitumorals. However, the occurrence of a multitude of 
adaptive mechanisms often leads to the appearance of drug resistance (41,42). Moreover, the 
effectiveness of EGFR-based therapies has not yet been validated in GBM. The observations here 
reported may help to set the bases for design novel therapeutic strategies to fight GBM, based on 
mTOR pharmacological inhibition. 
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Figure legends 
Fig.1 EGFR internalizes into GBM cells upon mTOR inhibition. (A) U87MG (upper panels), 
GL15 (middle panels) and primary GH2 cells (lower panels) were cultured in complete DMEM 
(CTR) or aminoacid- and serum- free medium (EBSS) or in DMEM in presence of 250nM Torin1 or 
100nM AZD8055 for 18h. Immunocytochemistry and confocal analysis for EGFR localization (red) 
were then performed. Hoechst 33342 was used to stain nuclei (blue). Scale bar, 30 μM. Western blot 
analysis of P-p70S6K and p70S6K was performed to check mTOR pathway inhibition. Hsp90 was 
used as loading control. The blots are representative of three independent experiments. (B) 
Immunocytochemistry and confocal analysis for EGFR localisation (red) were performed in U87MG 
cells, upon 2h and 4h Torin1 treatment. Western blot analysis of P-p70S6K and p70S6K was carried 
out to check mTOR inhibition by Torin1. Scale bar, 30 μM. 
Fig.2 EGFR de-localization in GBM cells is independent on canonical autophagy. (A) shCTR 
and shBECLIN1 GL15 cells (24) were cultured in DMEM (CTR) or EBSS media or in DMEM in 
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presence of 250nM Torin1 for 18 h and subjected to immunocytochemistry and confocal analysis for 
EGFR localisation (red) (right panels). Hoechst 33342 was used to stain nuclei (blue). Scale bar, 30 
μM. Western blot analysis of P62 and LC3 I/II was performed to check autophagy induction (left 
panel). A specific antibody for BECLIN1 was used to check the silencing efficiency. β-ACTIN was 
used as loading control. The blot is representative of three independent experiments. (B) U87 cells 
were transduced with GFP-LC3-expressing retrovirus as described in Material and Methods.  Infected 
cells, cultured in normal medium (CTR) or in DMEM containing 250nM Torin1 for 24h, were 
subjected to immunocytochemistry and confocal analysis for EGFR (red) and autophagosomes 
(green) localization. The images showing the merge of the two signals are shown in the right panels. 
Scale bar, 30 μM. 
Fig.3 EGFR is delivered to lysosomes upon mTOR inhibition in GBM cells. U87MG treated with 
Torin1 for 24h or untreated (CTR) were subjected to immunocytochemistry and confocal analysis for 
EGFR (red) and for different subcellular markers (green): Calnexin for endoplasmic reticulum (A), 
Giantin for Golgi cisternae (B), Tomm-20 for mitochondria (C) and Cathepsin D for lysosomes (D). 
The images showing the merge of the two signals are shown in the right panels. Inset containing a 
high magnification view of the merge image is also shown. Scale bar, 30 μM. Colocalization was 
assessed by calculating the Pearson’s correlation coefficient r (mean r in D: CTR, 0.2 ± 0.03; Torin1, 
0.75 ± 0.06).  
Fig.4 mTOR inhibition leads to a reduction of EGFR expression in GBM cells. (A, B) U87MG, 
GL15 were cultured in complete DMEM medium in presence (TORIN1) or not (CTR) of 250nM 
Torin1 and analysed at the indicated time points. Western blot analyses were performed by using a 
specific antibody for EGFR. HSP90 was used as loading control. (C) GH2 cells were cultured in 
complete DMEM medium in presence (TORIN1) or not (CTR) of 250nM Torin1 and analysed at the 
indicated time points. Western blot analyses were performed by using a specific antibody for EGFR. 
HSP90 was used as loading control. The graph represents the mean ± SE of three different 
experiments. Statistical significance: * P < .05 Student t-test ** P < .01 Student t-test.  
Fig.5 MAPK/ERK pathway is down-regulated upon mTOR inhibition in GBM cells. (A, B) 
U87MG and GL15 were cultured in complete DMEM medium in presence (TORIN1) or not (CTR) 
of 250nM Torin1 and analysed at 2h and 4h (A) and at 24h and 48h (B). Western blot analysis was 
performed by using specific antibodies for ERK1/2 and P-ERK1/2. HSP90 was used as loading 
control. (C) GH2 cells were cultured in complete DMEM medium in presence (TORIN1) or not 
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(CTR) of 250nM Torin1 and analysed at the indicated time points. Western blot analysis was 
performed by using specific antibodies for ERK1/2 and P-ERK1/2. HSP90 was used as loading 
control. The graph represents the mean ± SE of three different experiments. Statistical significance: 
* P < .05 Student t-test ** P < .01 Student t-test, *** P < .001 Student t-test.
Fig.6 mTOR inhibition leads to SRC activation. (A) U87MG cells were cultured in complete 
DMEM (CTR) or aminoacid- and serum- free medium (EBSS) or in DMEM in presence of 250nM 
Torin1 or 100nM AZD8055 for 18h. Western blot analysis was performed by using specific 
antibodies for the total (SRC) and the phosphorylated (Y416) form of SRC (P-Src). β-ACTIN was 
used as loading control. (B) U87MG cells were cultured in DMEM in presence of Torin1 pre-
incubating or not with 20µM PP2 inhibitor for the indicated time points. Western blot analysis was 
performed by using specific antibodies for the total (SRC) and the phosphorylated (Y416) form of 
SRC (P-Src). β-ACTIN was used as loading control. The graphs represent the mean ± SE of three 
different experiments. Statistical significance: ** P < .01 Student t-test *** P ≤ .001. (C) 
Immunocytochemistry and confocal analysis for EGFR localisation (red) were performed in U87MG, 
upon 6h and 24h of Torin1 and PP2 treatments, as indicated. Hoechst 33342 was used to stain nuclei 
(blue). Scale bar, 30 μM. 
Supplementary Fig.S1 EGFR is delivered to lysosomes upon mTOR inhibition in GL15 and in 
primary GH2 GBM cells. GL15 and GH2 GBM cells, cultured in complete DMEM medium in 
presence (TORIN1) or not (CTR) of 250nM Torin1, were subjected to immunocytochemistry and 
confocal analysis for EGFR (red) and for lysosomes (green). The images showing the merge of the 
two signals are shown in the right panels. Inset containing higher magnification views of the merge 
images are also shown. Scale bar, 30 μM. Colocalization was assessed by calculating the Pearson’s 
correlation coefficient r (for GL15: Ctr, 0.28 ± 0.01; Torin1, 0.7 ± 0.05. for GH2: Ctr, 0.2 ± 0.01; 













In this thesis, the role of autophagy in GBM biology was investigated through the analysis of different 
aspects involved in GBM pathogenesis. 
The research article I illustrates the effect of autophagy induction on Wnt/β-catenin signalling in 
GBM cells. The main results indicated that autophagy induction leads to an impairment of Wnt/β-
catenin signalling in GBM cellular models. Upon starvation and mTOR inhibition, we observed a 
strong down-regulation of β-catenin target genes and, unlike other models, a marked relocalization of 
the protein within the cell. Notably, β-catenin appears mainly localised in plasma membrane areas 
and co-localises with N-cadherin in correspondence of cell-cell contacts, suggesting the role of β-
catenin in supporting the mesenchymal-to-epithelial-like transition. Accordingly, a decrease of the β-
catenin nuclear fraction occurs, coupled to an accumulation in the cytosolic compartment.  
Based on our results and on previous findings collected by Catalano and colleagues in 2015, it is now 
clear that autophagy induction contributes to the switch of GBM cells from a mesenchymal phenotype 
to an epithelial-like one.  
 
In the manuscript II, the role of mTOR in EGFR trafficking was evaluated. Results obtained in the 
first research article led us to investigate EGFR expression and activity in our GBM cellular models. 
This receptor is often overexpressed and mutated in several cancer types, as well as in GBM, resulting 
in a constitutive activation of downstream proliferative signalling pathways. We observed that, upon 
several autophagy stimuli, EGFR is internalised within the cell, becoming unavailable for putative 
ligand binding on cell membrane. This delocalization results in EGFR delivery to lysosomes for 
degradation. According to this observation, a decrease of EGFR expression occurs in GBM cells upon 
the same treatments. 
Canonically, EGFR lysosomal degradation is stimulated upon the interaction of the receptor with its 
growth factor ligands EGF. On the other hand, low concentration of extracellular ligands results in a 
higher recycling rate of the receptor to cell membrane. 
In this work, instead, we demonstrated that EGFR is delivered to lysosomes without any EGF external 
stimulation. 
Surprisingly, EGFR internalization appears to be independent on autophagy stimulation, but a 
consequence of mTOR inhibition. In fact, by using Beclin-1 silenced cells, we observed that silencing 




It is known that EGFR activation results in the induction of downstream pathways, including 
MAPK/ERK pathway, involved in several physiological and pathological processes such as 
proliferation, differentiation, growth, migration and apoptosis.  
Interestingly, data obtained in the manuscript II also show that EGFR internalization leads to a 
negative regulation of MAPK/ERK pathway, confirmed by the strong reduction of the phosphorylated 
form of ERK 1/2 in cells that underwent mTOR inhibition, compared to control cells. 
These results suggest that mTOR is required for EGFR trafficking and, therefore, for sustaining 
proliferative signalling.  
Finally, we also found that the protein kinase Src is likely involved in the EGFR internalization, 
resulting more phosphorylated upon mTOR inhibition. To confirm that, by inhibiting both Src 
phosphorylation and mTOR pathway, the internalization of EGFR is prevented. The receptor appears, 
in fact, mainly localized in plasma membrane, as well as in control cells.  
To date, EGFR is a promising therapeutic target in cancer treatment. Standard strategies used against 
EGFR, such as monoclonal antibodies and tyrosine kinase inhibitors, however, often lead to a 
multitude of adaptive mechanisms and appear ineffective in GBM therapeutical approaches. In a 
prospective vision, the inhibition of mTOR could be an effective alternative tool to contrast GBM 
progression by means of EGFR internalization and degradation.  
Although controversial works about the autophagy role in cancer, as also reported in our published 
review, the findings shown in this doctoral thesis support the idea that targeting the autophagy process 
could be an effective strategy in the fight against this aggressive and still incurable cancer. 
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